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ABBREVIATIONS
ABBREVIATIONS
A96I altered peptide ligand differing from PCC (88–104) by isoleucine substitution 
for alanine at position 96 (KAERADLIIYLKQATAK); low TCR affinity
ACID activation-induced cell death
Ag antigen
Akt protein kinase B
ALPS autoimmune lymphoproliferative syndrome
AML acute myeloid leukemia
AP-1 activation protein 1
APC antigen-presenting cell
BAY
11-7082
(E)-3-(4-methylphenylsulfonyl)-2-propenenitrile; 
specific inhibitor of IκB kinase (IKK)
BFA brefeldin A
BrdU 5-bromo-2’-deoxyuridine
BSA bovine serum albumin
CARMA1 CARD and MAGUK domain-containing protein-1
CBM complex composed of CARMA1, Bcl10, MALT1
CDK cyclin-dependent kinase
CFSE carboxyfluorescein diacetate succinimidyl ester
ConA concanavalin A
CVT-313 2(bis-(hydroxyethyl)amino)-6-(4-methoxybenzylamino)-9-isopropyl-purine; 
specific inhibitor for CDK2
DAG diacylglycerol
DAPI 4’6-diamidino-2-phenylindole
DC dendritic cell
DMSO dimethyl sulfoxide
DN double negative
DNA deoxyribonucleic acid
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
ERK1/2 extracellular signal-regulated kinase 1/2
FACS fluorescence-activated cell sorting
FasL Fas ligand
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ABBREVIATIONS
FCS fetal calf serum
FITC fluorescein isothiocyanate
GEF guanine nucleotide exchange factor
GM-CSF granulocyte-macrophage colony-stimulating factor
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
hrIL-2 human recombinant interleukin-2
IFN interferon
Ig immunoglobulin
IκBα nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, 
alpha
IKKα IκB kinase alpha
IKKβ IκB kinase beta
IL interleukin
IP3 inositol 1,4,5-trisphosphate
ITAM immunoreceptor tyrosine-based activation motif
LAT linker for activation of T cells
Lck lymphocyte-specific protein tyrosine kinase
lpr lymphoproliferation
MALT1 mucosa-associated lymphoid tissue 1
MAPK mitogen-activated protein kinase
MHC major histocompatibility complex
MS multiple sclerosis
NEMO NF-κB essential modulator
NFAT nuclear factor of activated T cells
NF-κB nuclear factor –kappa B
NLS nuclear localization sequence
PBS phosphate buffered saline
PCC pigeon cytochrome C (KAERADLIAYLKQATAK); dominant agonist peptide 
PE phycoerythrin
PI propidium iodide
PI3K phosphatidylinositol 3 kinase
PIP2 phosphatidylinositol 4,5-bisphosphate
PKCθ protein kinase C-theta
PMA phorbol myristate acetate
poly(dI-dC) polydeoxy(Inosinate-Cytidylate Acid), sodium salt
Rb retinoblastoma
RT room temperature
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ABBREVIATIONS
SD standard deviation
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
SLE systemic lupus erythematosus
Src sarcoma tyrosine kinase
TCR T cell receptor
TCRtg transgenic TCR
tg transgenic
TH helper T cell
TNFα tumor necrosis factor alpha
Treg regulatory T cell
U0126 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene; 
specific inhibitor for MEK
ZAP70 zeta-chain-assicoated protein kinase 70 kDa
zVAD benzyloxycarbonyl-Val-Ala-Asp (Ome) fluoromethylketone; apoptosis inibitor 
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PRESENTACIÓN
PRESENTACIÓN
El delicado equilibrio entre activación, proliferación y muerte de las células T es crucial para 
el desarrollo y el mantenimiento de la tolerancia, una característica importante del sistema inmune. 
Estos procesos deben estar muy controlados, ya que una mínima desregulación puede dar lugar a 
graves defectos en el sistema inmune.  En un trabajo previamente publicado por nuestro equipo, 
mostramos que la ausencia de p21 – una molécula conocida como inhibidor del ciclo celular – 
provoca la hiperproliferación de las células T de memoria conduciendo al desarrollo de una patología 
autoinmune tipo lupus56.  Sin embargo, un elevado porcentaje de células T de memoria se identificó 
en los ratones deficientes en p21.  Por lo tanto, estaba por determinar el modo de actuación de p21 
y su influencia en la activación de las células T.  En ésta tesis usamos diferentes sistemas de cultivos 
in vitro y modelos de ratón in vivo para examinar el possible papel de p21 en la activación de las 
células T y para determinar la función de p21 en este proceso. 
Definición de los objetivos de ésta tesis:
Estudiar el efecto de p21 en la activación y la proliferación de las células T en distintos 1. 
sistemas in vitro e identificar las rutas de activación controladas por p21.
Examinar si p21 regula la activación de las células T de forma independiente de su papel 2. 
como inhibidor del ciclo celular.
Definir la influencia de p21 en la activación de las células T en respuesta a antígenos de 3. 
afinidad baja, un evento que se considera crítico para el desarrollo de autoinmunidad.
Analizar el efecto de la ausencia de p21 en conjunto con el defecto en Fas (4. lpr) en la actvación 
de las células T.
Determinar el efecto terapéutico de la sobre-expresión de p21 restringida a las células T en 5. 
ratones B6/lpr .
En esta tesis se ha confirmado que p21 controla la activación de las células T de memoria/
efectoras vía CDK2 después de una estimulación repetida.  Se comprobó que p21 no controla 
eventos de activación proximales al TCR pero podría actuar a nivel de la PKCθ o en las vías de 
5
PRESENTACIÓN
activación reguladas por PKCθ ya que está localizado en el citoplasma de las células T de memoria/
efectoras.
p21 controla la respuesta proliferativa de las células T de memoria/efectoras regulando de forma 
negativa las vías de activación de ERK1/2 y NF-κB.  En ausencia de p21, se observó la sobreactivatión 
de ERK1/2 y NF-κB en éstas células, lo cual lleva a una hiperproliferación y una mayor producción de 
citoquinas pro-inflammatorias (IFNγ, IL-2).
Analizando la respuesta de células T presentando un TCR transgénico, se detectó una elevada 
respuesta de las células T p21-/- re-estimuladas in vitro con un antígeno específico de baja afinidad. 
Este resultado apunta a un menor umbral de activación en las células T de memoria deficientes en 
p21 y relaciona la hiperactivación detectada en éstas células con una respuesta frente a antígenos 
propios.
El estudio de ratones B6/lpr deficientes en p21 (B6/lpr-p21-/-) ha confirmado la relevancia 
biológica de nuestros resultados.  En ausencia de p21, las manifestaciones de la enfermedad 
autoinmune empeoran considerablemente causando finalmente la muerte.  La hiperactivación y 
los elevados niveles de IFNγ detectados en las células T CD4+ de memoria B6/lpr-p21-/-podrían ser 
responsables del desarrollo de una enfermedad autoinmune severa en estos ratones. 
Finalmente, estudios con ratones expresando un p21 transgénico humano específicamente en 
las células T revelaron una notable reducción en la activación de las células T CD4+ de memoria 
B6/lpr-p21tg, asi como en la producción de IFNγ.  Este fenotipo conlleva una considerable mejoría 
de las manifestaciones autoinmunes en los ratones B6/lpr-p21tg respecto a las manifestaciones 
observadas en los ratones B6/lpr.
En general, los datos presentados en esta tesis demuestran un importante papel de p21 como 
regulador negativo de la activación de las células T de memoria, en concreto de la población de 
células T potencialmente auto-reactivas y de su producción de IFNγ.  Por lo tanto, p21 puede ser 
considerado como supresor de la autoinmunidad y podría servir para el desarrollo de nuevas 
estrategias terapéuticas en ciertas enfermedades autoinmunes.
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ABSTRACT
 The maintenance of T cell tolerance, which is established by the fine balance between 
Txcell activation, proliferation and apoptosis, is crucial to avoid of autoimmunity development. 
Lack of p21, a cell cycle inhibitor also implicated in effector/memory T cell activation, is linked to 
SLE in human patients; in accordance, C57BL/6 p21-deficient mice lose tolerance and develop mild 
autoimmune disease with age.  Here we study the effect of p21 on T cell activation.  Whereas 
p21 regulated activation of effector/memory T cells in a CDK2-independent manner, it had no 
effect on naïve T cells.  We also found that cytoplasmic p21 is unrelated to TCR proximate events, 
but controls memory T cell activation via downstream MAPK and NF-κB pathways.  Lack of p21 
caused hyperactivation of ERK1/2 and NF-κB in memory-phenotype T cells, leading to increased 
proliferation and pro-inflammatory cytokine production (IFNγ, IL-2).  Stimulation of TCR-transgenic 
(tg) T cells with specific antigens in vivo confirmed our finding that p21 is involved in effector/
memory T cell activation.  In response to in vitro stimulation with low affinity antigens that mimic 
auto-antigens, p21 influenced the activation threshold of effector/memory T cells, a critical factor 
for tolerance maintenance and autoimmunity suppression.  In lupus-prone B6/lpr mice, lack of 
p21 in hyperactivated memory T cells caused increased production of pro-inflammatory cytokines 
such as IFNγ, as well as marked aggravation of lupus-like disease manifestations, leading to death. 
These effects were reversed by T cell-specific overexpression of p21.  B6/lpr-p21tg mice showed 
reduced memory T cell activation and lower IFNγ levels, which efficiently restrained autoimmunity 
development.  By inhibiting T cell activation and reducing pro-inflammatory cytokine production 
in auto-reactive, but not in normal T cells after repeated antigen encounter, p21 might thus have a 
therapeutic effect as a suppressor of autoimmunity.
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1.  INTRODUCTION
1.1 The Immune System
In the course of evolution, vertebrates developed complex mechanisms to protect themselves 
against potential pathogens to which they are constantly exposed.  The basic challenge of the 
immune system is to distinguish between self (originating from the same organism) and non-self 
particles (such as bacteria, viruses or parasites).  This process is tightly regulated; in consequence, 
any dysregulation is likely to cause severe damage to the organism.
Once a pathogen manages to penetrate physical and chemical surface barriers and invades 
the body, the innate immune system is activated1.  This immediate and nonspecific cellular defense 
mechanism is provided primarily by phagocytes (macrophages, neutrophils, eosinophils, basophils 
and dendritic cells; DC), which recognize foreign molecular patterns and subsequently engulf and 
destroy the pathogen.  Small particles of engulfed pathogens are presented on the surface of so-
called antigen-presenting cells (APC; mainly macrophages and DC), where they can be recognized by 
cells of the adaptive immune system.  APC also release pro-inflammatory cytokines to amplify the 
inflammatory response.  In addition, natural killer (NK) cells recognize infected or malignant tumor 
cells and free cytolytic chemicals to promote cell lysis.
Although this first-line defense is effective in controlling and clearing infectious agents, 
many pathogens developed strategies to escape the nonspecific mechanisms of the innate immune 
system.  Therefore, the acquired immune system provides adaptive protection towards antigens (Ag) 
and, in contrast to the innate immune system, is able to develop an immunological memory2.  This 
kind of immune response is mediated by B and T lymphocytes, which circulate constantly through 
secondary lymphatic organs and present an immense repertoire of specific surface receptors (BCR/
TCR) generated from rearranged gene segments.  Upon contact of a B cell with a foreign substance, 
the specific BCR (B cell receptor) mediates endocytosis of the antigen, which is subsequently 
processed and presented embedded in MHC class II molecules on the B cell surface.  Interaction 
with a primed T helper cell of the appropriate specificity then leads to B cell activation, Ig class 
switch recombination and differentiation into plasma cells that secrete antibodies (Ab) to the target 
antigen (humoral immunity).  Finally, immune complexes (Ab-Ag) are neutralized by phagocytosis.
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Recognition of a specific Ag bound to MHC II molecules on the APC surface by the 
corresponding TCR (T cell receptor) leads to activation and proliferation of T helper cells (CD4+) (for 
details see 1.3).  This type of effector T cell acts indirectly by releasing chemical mediators (cytokines 
and chemokines) to enhance the inflammatory response, and directly by activating B cells through 
cell-cell-interaction.  Cytotoxic T cells (CD8+), in contrast, effect cell-mediated immunity; they 
recognize Ag presented on MHC I molecules and release cytotoxins (perforin, granzymes) to directly 
lyse foreign, virus-infected or cancer cells.
After the first exposure to a specific antigen, an immunological memory is generated to 
protect the organism from subsequent infections.  Both B and T cells are able to develop resting, 
long-lived memory cells, able to mediate a rapid, effective immune response after secondary 
challenge with the same pathogen (for details see 1.4).
1.2 Establishment of self-tolerance during T cell development
T lymphocytes are able to generate a wide variety of different TCR from the same genomic 
sequence by a process known as somatic recombination3.  In this way, unique antigen-binding sites 
are determined randomly, and some of them might be able to recognize auto-antigens.  To avoid 
immune responses towards self-antigens that could harm the organism, auto-reactive lymphocytes 
are inactivated or eliminated directly.  During thymocyte development, T cell precursors acquire self-
tolerance to prevent autoimmunity4. Bone marrow-derived T cell progenitors are attracted to the 
thymus (by adhesion molecules and chemokines), where they pass through different developmental 
stages and corresponding TCR quality control checkpoints to establish a non-self-reactive T cell 
pool5.  Two general types of T cells can be distinguished.  The majority (95%) of the T cells belong to 
the αβ T cell lineage; only about 5% express the alternative γδTCR6.
During the first stage of T cell development, double negative T cell precursors (CD4-CD8-; 
DN) start with the recombination of TCR gene segments, resulting in preTCR expression.  Ligand-
independent signals provided by the preTCR lead to CD4/CD8 co-expression (CD4+CD8+; double 
positive; DP) and further recombination of TCR genes7.  Once a functional antigen receptor is 
expressed, thymocyte development is continued in the thymus and the survival of TCRαβlow CD4+CD8+ 
cells depends critically on the TCR affinity for self-peptide:MHC complexes.
12
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1.2.1 Central Tolerance
The thymic microenvironment has several mechanisms to ensure T cell tolerance before 
releasing mature T cells to peripheral tissues.  This so-called central tolerance is established by 
positive and negative selection processes8 (“affinity model of selection”).
In the thymic cortex, CD4+CD8+ DP immature T cells undergo ligand-dependent selection by 
binding self-peptide:MHC complexes on cortical thymic epithelial cells (cTEC).  Thymocytes expressing 
TCR molecules that are not able to bind self-peptide:MHC complexes are deleted by apoptosis.  In 
contrast, low-affinity engagement of the TCR selectively induces survival (positive selection) and 
subsequent differentiation to mature CD4/CD8 single positive thymocytes9 (SP; TCRαβhighCD4+CD8- 
and TCRαβhighCD4-CD8+); the respective co-receptor not involved in MHC recognition is lost.
Positively selected SP T cells travel on towards the thymic medulla, where they are exposed 
to a diversity of tissue-specific self-antigens presented by medullary thymic epithelial cells (mTEC) 
and DC.  SP thymocytes that harbor high affinity TCR to self-antigens are potentially harmful; these 
auto-reactive cells are eliminated from the T cell pool by apoptosis (negative selection).  In contrast, 
low affinity interaction of the TCR with self-peptide:MHC complexes ensures T cell survival and 
subsequent release of functional, mature T cell clones to peripheral tissues10.
Nonetheless, high affinity interaction of TCR molecules with self-peptide:MHC complexes in 
the presence of survival cytokines such as IL-2 or TGFβ induces the development of another important 
T cell type, the CD4+CD25+ naturally-occurring regulatory T cells (nTreg). This process, called clonal 
diversion, requires the expression of the transcription factor FoxP3 and rescues potentially harmful 
auto-reactive clones, providing them with suppressive or regulatory functions11 (see alsox1.3.2).
1.2.2 Peripheral Tolerance
As not all self-antigens are thymically expressed (such as food-derived or developmental 
antigens) and some potentially auto-reactive T cells manage to escape central tolerance, additional 
immune surveillance mechanisms operate in the periphery, preserving the state of tolerance and 
preventing inappropriate T cell reactions12.
Activation of naïve mature T cells as well as subsequent proliferation and cytokine expression 
require, in addition to TCR engagement, positive co-stimulatory signals mediated by CD28 binding 
to B7 molecules (CD80/B7-1 or CD86/B7-2) expressed on APC. In the absence of an inflammatory 
response, quiescent APC present low surface levels of B7 molecules. When auto-reactive T cells 
are exposed to self-peptide MHC complexes in absence of CD28-co-stimulatory signals, activation 
13
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of naïve T cells fails and a state of hypo-responsiveness, also known as clonal anergy, is induced. 
Anergic cells are characterized by their inability to proliferate and to produce IL-2 due to insufficient 
TCR signaling, and hence remain unresponsive to antigens13.
Besides the positive second signal provided by CD28, other molecules provide negative 
regulation to limit anti-self T cell responses and to establish tolerance.  One of these negative 
receptors is CTLA-4: like CD28, it presents high affinity for B7 family co-stimulatory molecules and 
thus restricts B7 interaction with CD28 in a competitive way.  In consequence, CTLA-4 mediates 
negative signals to prevent expansion of autoreactive T cell clones14.  Another essential inhibitory 
co-stimulatory molecule is PD-1 (programmed death 1).  By interaction with one of its ligands (PD-
L1 or PD-L2), efficient TCR engagement is prevented and self-reactive T cells remain in an anergic 
state15.  Both CTLA-4 and PD-1 are crucial for inducing and preserving functional inactivation of 
auto-reactive T cell clones in an antigen-specific manner.  The absence CTLA-4 or PD-1 leads to 
impaired anergy induction and finally to development of autoimmune diseases16-19.
Another type of tolerance mechanism acts when potentially autoreactive naïve T cells 
migrate to the periphery but the respective antigen is isolated within inaccessible tissues.  This 
physical separation (e.g., blood-brain barrier) prevents an encounter with the antigen and subsequent 
activation of the auto-reactive T cell, a phenomenon known as clonal ignorance.
Other cell types, such as regulatory T cells (Treg), are also involved in mediating peripheral 
tolerance. Treg suppress auto-reactive T cells by expression of immunosuppressive cytokines such as 
TGFβ and IL-10 and thus prevent autoimmune responses20.
Upon activation of an autoreactive T cell, an intrinsic tolerance mechanism known as 
activation-induced cell death (AICD) is triggered.  Repeated T cell stimulation by self-antigens induces 
the co-expression of a death-domain-containing receptor named Fas (CD95) and its cognate ligand 
FasL (CD95L)21,22.  In the presence of high IL-2 levels, Fas-FasL interaction triggers T cell apoptosis by 
activating caspase 8 (for details see 1.5.1).
Together, these tolerance mechanisms cooperate to ensure the generation of a diverse pool 
of naïve mature T cells able to induce effective immune responses to pathogen-derived antigens in 
the context of MHC molecules, while tolerating the self-antigens present.  This fine balance of self-
tolerance is precisely controlled to avoid autoimmune pathology; failure of any of these tolerance 
mechanisms leads to an inappropriate T cell response towards self-antigens and thus results in 
development of autoimmune diseases (see 1.4.3).
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Figure 1.1.  Overview of the tolerance mechanisms that shape the T cell repertoire.  A. Central tolerance.  Bone marrow-
derived T cell precursors undergo a strict selection process in the thymus to establish an efficient T cell pool.  In the 
thymic cortex, numerous CD4+CD8+ DP T cells undergo apoptosis because they are unable to bind to self-peptide:MHC 
complexes; only clones that recognize self-peptide:MHC complexes survive (positive selection) and develop to CD4+ or 
CD8+ SP T cells.  In the thymic medulla, T cells that engage self-peptide:MHC complexes with low affinity are eliminated 
by apoptosis (negative selection), whereas low-affinity interaction leads to survival and release of mature T cells to the 
periphery.  B.xPeripheral tolerance.  Different strategies help to prevent an immune response of mature T cells towards 
auto-antigens in the periphery, including suppression by regulatory T cells, anergy, negative regulation (via CTLA-4 or 
PD-1), activation-induced cell death (AICD) or clonal ignorance.
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1.3 T cell activation
1.3.1 TCR activation pathways
Antigen-specific interaction of the TCR with peptide:MHC II complexes on APC, together 
with co-stimulatory signals provided by CD28, lead to T cell activation23,24 (Fig. 1.2A).  Following 
TCR stimulation, the tyrosine kinases Lck and Fyn are activated and phosphorylate CD3 ζ-chain 
ITAM (immunoreceptor tyrosine-based activation motif) as well as ZAP7025, which in turn recruits 
several downstream molecules such as the two adaptor proteins SLP-76 and LAT to form an active 
signaling complex26.  Phospholipase C gamma (PLCγ) is bound and activated by this complex, and 
in consequence mediates the hydrolysis of PIP2 (phosphatidylinositol 4,5bisphosphate) into the 
second messengers IP3 (inositol trisphosphate) and DAG (diacylglycerol)
27.  IP3 mainly induces 
nuclear translocation of NFAT (nuclear factor of activated T cells), whereas DAG influences different 
T cell activation pathways.
The hydrophilic second messenger IP3 diffuses through the cytosol and binds to its 
receptor (IP3R) on membranes of the ER (endoplasmic reticulum), which triggers depletion of 
ER Ca2+ stores into the cytosol and promotes a transient elevation of intracellular free Ca2+ levels 
(Fig.1.2B).  Accumulation of cytosolic Ca2+ activates calmodulin (CaM), which in turn activates the 
protein phosphatase calcineurin.  Activated calcineurin dephosphorylates NFAT proteins28, which 
appear to be heavily phosphorylated and thereby retained within the cytoplasm of resting T cells. 
Dephosphorylated NFAT proteins undergo conformational changes, leading to exposure of a nuclear 
localization sequence (NLS), which finally permits NFAT nuclear translocation and induction of 
NFAT-mediated gene transcription.  NFAT-activated genes are involved in activation of T cells and in 
generation of T cell tolerance29.
The membrane-diffusible second messenger DAG recruits and activates different effector 
molecules.  PKCθ (protein kinase C) and RasGRP (RAS guanyl nucleotide-releasing protein) are two 
of the best characterized DAG targets in T cells30,31.  Together, they control the initiation of two 
crucial signaling branches in T cell activation; the MAPK (mitogen-activated protein kinase) cascade 
and the NF-κB (nuclear factor-κB) pathway.
Together with SOS (son of sevenless), the GEF (guanine exchange factor) RasGRP promotes 
activation of Ras-GTP (Fig. 1.2C), which leads to a concatenation of phosphorylation events among 
the MAP kinases Raf-1, Mek-1 and ERK-1/232.  These events finally result in the assembly of the AP-1 
(activator protein 1) transcription factor complex.  AP-1 is composed of homo- and heterodimers of 
Fos and Jun family proteins and plays a key role in T cell activation and IL-2 production33.
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The NF-κB/Rel family of transcription factors also has a central function in T cell activation. 
In resting T cells, NF-κB dimers are found within the cytosol bound to inhibitory IκB molecules, which 
prevent NF-κB translocation to the nucleus by masking its nuclear localization sequence (NLS)34. 
Besides its contribution to the activation of the MAPK pathway, PKCθ is a critical factor for initiation 
of the NF-κB pathway.  DAG-activated PKCθ phosphorylates CARMA1, which leads to formation 
of the trimolecular CMB complex composed of CARMA1, Bcl10 and MALT1 (Fig. 1.2D)35,36.  The 
CBM complex promotes activation of IKK (IκB kinase) complexes composed of the catalytic subunits 
IKKα and IKKβ, and IKKγ/NEMO (NF-κB essential modulator) as a regulatory subunit, which in turn 
mediates the phosphorylation of inhibitory IκBα molecules37.  This is an essential step in NF-κB 
activation, as it leads to ubiquitinylation and subsequent proteosomal degradation of inhibitory IκBα 
proteins38.  In consequence, NF-κB dimers are released in the cytosol and are allowed to translocate 
to the nucleus, where they regulate transcription of pro-inflammatory genes including cytokines, 
chemokines, cell cycle regulators and adhesion molecules37,39.
The crosstalk between the pathways described above determines the outcome of the 
immune response, and cooperative interaction of the transcription factors NFAT, AP-1 and NFκB 
promotes T cell activation, proliferation and pro-inflammatory cytokine production.  As these events 
are also crucial for induction and maintenance of T cell tolerance and homeostasis, a wide variety of 
human diseases is associated with dysregulated pathway activities.
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Figure 1.2.  Overview of the main TCR activation pathways.  A. TCR proximate events.  Following interaction of the TCR 
with its specific peptide:MHC complex on APC, ITAM motifs within CD3 ζ-chains are phosphorylated.  Activated ZAP70 
and LAT induce the formation of a multi-molecular signaling complex and activation of PLCγ.  The second messengers IP3 
and DAG subsequently trigger several downstream signaling pathways.  B. NFAT pathway.  IP3 induces calcium-dependent 
calcineurin activation, and NFAT dephosphorylation leads to its nuclear translocation.  C. MAP kinase pathway.  Via RasGTP, 
DAG activates the MAPK phosphorylation cascade (Raf-1, MEK1, ERK1/2), finally resulting in AP-1 assembly.  D. NF-κB 
pathway.  PKCθ induces the formation of the CBM complex, which in turn promotes activation of IKK complexes.  After 
phosphorylation and degradation of IκBα, NF-κB dimers are released and translocate to the nucleus.  The transcription 
factors NFAT, AP-1 and NF-κB finally induce expression of pro-inflammatory cytokines and other genes involved in T cell 
activation and proliferation.
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1.3.2 T cell subsets
After interaction with APC that present specific antigens on MHC II molecules on their 
surface, CD4+ T cells are activated and exert their effector function via production of proinflammatory 
cytokines, to activate and attract B cells and macrophages towards the source of infection.  During 
an inflammatory response, naïve CD4+ T helper (TH) cells can differentiate into several subtypes of 
effector T helper cells, depending on the cytokine milieu present during TCR activation and other 
factors such as antigen dose or co-stimulators.  Based on their cytokine profile, activated CD4+ T cells 
can be divided into the following major effector subtypes40: TH1, TH2, TH17, and Treg.  Tight control 
among these functional subpopulations is required to establish polarized immune responses and to 
maintain tolerance.
In the presence of IL-12 and IFNγ, uncommitted CD4+ T cells develop into mature TH1 cells, 
while IL-4 favors the generation of TH2 cells.  The characteristic cytokines produced by TH1 cells 
are IFNγ, IL-2 and TNFα, which activate macrophages and promote pro-inflammatory immune 
responses towards intracellular pathogens40,41.  TH2 cells typically produce large amounts of IL-4, -5, 
-10 and -13 to facilitate the clearance of extracellular pathogens as well as activation of eosinophils 
and IgE production by B cells.  In addition, several transcription factors influence the differentiation 
towards TH1 or TH2 cells; T-bet, STAT1 and STAT4 promote generation of TH1 cells, whereas GATA-3 
and STAT6 support the production of TH2 cells
40,41. The development of TH1/TH2 cells is mutually 
antagonistic, and a fine balance is crucial to establish effective protection against pathogens and to 
prevent autoimmunity.  Aberrant activation of TH1 cells is linked to the development of autoimmune 
diseases such as systematic lupus erythematosus (SLE)42, rheumatoid arthritis (RA) and multiple 
sclerosis (MS), while asthma and other allergies are induced by dysregulated TH2 activity (see 
1.4.2)43.
The development of TH17 cells is coupled to the presence of TGFβ, IL-6 and IL-23.  TH17 
cells mainly secrete the pro-inflammatory cytokine IL-17, thereby facilitating innate immune 
responses towards extracellular bacteria and fungi44.  Elevated IL-17 levels are associated with some 
autoimmune diseases45,46.
In addition to naturally arising regulatory T cells (nTreg), which develop in the thymus (see 
1.2.1 for details), naïve CD4+ T cells can convert into inducible Treg (iTreg) in the periphery.  The presence 
of IL-10 and TGFβ leads to generation of iTreg cells, which play a crucial role in downregulation of 
immune responses, maintenance of peripheral tolerance and prevention of autoimmunity47. 
Following activation, iTreg cells secrete the immune-suppressive cytokines TGFβ and IL10 to regulate 
inflammatory responses.  Defective Treg functions result in development of autoimmune disorders 
or attenuated immunity47.
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Figure 1.3. Overview of the principal T cell subsets.  After activation by antigen encounter, naïve T cells differentiate into 
distinct effector T cells to ensure effective antigen clearance.  The presence of a number of cytokines as well as transcription 
factor expression promote differentiation to TH1, TH2, TH17 or Treg cells, which in turn release particular cytokine subsets to 
promote (or inhibit) specific immune responses.
1.4 T cell homeostasis and its link to autoimmunity
1.4.1 T cell homeostasis during a normal immune response
Once naïve T lymphocytes (classified as CD44low) recognize their specific antigen on MHC 
molecules presented by APC, they are activated and begin to proliferate intensely.  This process, 
known as clonal expansion, amplifies the effector function by providing an elevated number of 
activated CD44high effector T cells to fight the infection48,49.(Fig. 1.4).  After eliminating the antigen, 
the activated lymphocytes undergo apoptosis during the contraction phase, to establish T cell 
homeostasis and prevent autoimmunity50,51.  A small proportion of those cells survive, however, 
and evolve into memory T cells (CD44highCD62Llow) to face subsequent infections in a faster, more 
efficient way.  If the same antigen is recognized by the immune system, resting memory T cells 
differentiate immediately to activated/memory T cells (CD44highCD62Lhigh), thus ensuring rapid antigen 
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clearance52.  Inflammatory reactions must be precisely controlled to prevent overreaction of the 
immune system.  The rapid clonal expansion of naïve T cells after antigen encounter is compensated 
by induced cell death of activated T lymphocytes after antigen clearance; this balance is known as 
T cell homeostasis48-51.  Proliferation and apoptosis cooperate to ensure optimal immune responses 
and, at the same time, to protect the organism from autoimmunity.  If one of these processes is 
defective, the proportion of naïve and memory T cells is altered.  In consequence, tolerance is lost 
and autoimmune diseases might arise.
Figure 1.4.  The course of a normal immune reaction.  During a primary immune response, naïve T cells are activated, 
expand rapidly and evolve into effector T cells.  After antigen elimination, effector T cells undergoapoptosis and only a 
few memory T cells survive.  Upon re-encounter with the same antigen, activated memory T  cells provide a fast, effective 
secondary immune response.
1.4.2 Defective T cell homeostasis leads to autoimmunity
T cell activation, proliferation and death are the three most important mechanisms involved 
in establishment and maintenance of T cell tolerance.  Defects in any of these events cause break of 
tolerance, finally resulting in development of autoimmune diseases.  Regulatory elements are thus 
crucial to restrict T cell activation, expansion and apoptosis and to keep autoimmunity at bay.
Complete T cell activation depends critically on positive co-stimulatory signals of CD28, 
initiating intracellular activation pathways that drive T cell proliferation.  Other co-stimulatory 
molecules, such as PD-1 and CTLA-4, provide inhibitory signals that prevent T cell overactivation 
eﬀector
phase
memory 
phase
clonal
expansion
steady
state
antigen
recognition
memory
activation
re-encounter
with antigen
ex
pa
ns
io
n
naïve
CD4+ T cells
activation
di
ﬀe
re
nti
ati
on
antigen elimination/
clearance
eﬀector T cells
contraction
phase
surviving 
memory T cells
time after antigen exposure
m
ag
ni
tu
de
 o
f T
 c
el
l r
es
po
ns
e
CD44low 
CD44high 
CD44high CD62L-
CD44high CD62L+
            IFNγ
IL-2
21
1.  INTRODUCTION
and, in consequence, hyperproliferation (see also 1.2.2).  Absence of PD-1 or CTLA-4 leads to loss of 
tolerance, massive lymphoproliferation and development of lupus-like disease in PD-1-/- and CTLA-/- 
mice16,17,53, and PD-1 is implicated in human SLE54.  Differentiation into distinct T cell subtypes after 
activation (see also 1.3.2) can also influence loss of tolerance and development of autoimmune 
diseases.  Pro-inflammatory cytokines produced by TH1 cells
55 (IFNγ) and TH17 cells
45 (IL-17) are 
associated with anti-DNA autoantibody production in murine and human SLE.
Another crucial element in T cell tolerance and homeostasis is cell cycle control, especially 
the regulation of memory T cell proliferation.  The absence of the cell cycle inhibitor p21 leads 
to development of lymphadenopathy and lupus-like autoimmune disease due to uncontrolled 
memory T cell expansion, as previously shown by our group56,57 (see also 1.6.3).  Similarly, other 
cell-cycle-associated molecules are crucial for maintenance of T cell tolerance, as development of 
autoimmune disease is observed in Gadd45α-/-, Gadd45β-/-Gadd45γ-/- and E2F2-/- mice58-60.  Not only 
memory T cells show aberrant proliferation levels; DN (CD8- CD4-) T cell hyperproliferation was also 
observed in SLE patients61.  Accumulating DN T cells were are implicated in the production of anti-
DNA autoantibodies62 and are responsible for elevated levels of IL-1761.
Fas-induced apoptosis was thought to be the main regulatory mechanism of T cell restriction 
during the contraction phase, controlling T cell tolerance and homeostasis63.  Several studies show 
that Fas-deficient T cells fail to undergo apoptosis in vitro, and lpr mice present autoimmune 
manifestations due to defective homeostasis64 (see 1.5.2).  Similar phenotypes are observed 
in mice that lack the pro-apoptotic molecule Bim, as well as in mice that overexpress the anti-
apoptotic molecule Bcl-265.  Precise apoptosis regulation is thus closely linked to establishment and 
maintenance of T cell homeostasis.
1.5 Fas deficiency in mice and men
1.5.1 Fas-dependent apoptotic pathway
In physiological conditions, the immune system must restrict the number of activated 
lymphocytes after pathogen clearance to ensure T cell homeostasis and tolerance (see 1.4.1).  This 
is achieved mainly by AICD via Fas (CD95, APO-1), a member of the tumor necrosis factor (TNF) 
receptor family, expressed as a homotrimer on the surface of T cells66.  After T cell activation in the 
presence of IL-2, expression of its ligand FasL (CD95L, CD178) is induced and Fas-FasL interaction 
leads to the recruitment of the adaptor molecule FADD (Fas-associated death domain protein) to 
the death domains within the cytoplasmic tail of Fas67,68 (Fig. 1.5).  FADD initiates the formation of 
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DISC (death-inducing signaling complex), including pro-caspase-869 which subsequently undergoes 
conformational changes that allow its proteolytic autoprocessing and assembly of the enzymatically 
active caspase-8 form.  The effector caspases-3 and -7 are then mobilized within the cytoplasm, 
which in turn induce morphological changes characteristic of apoptotic cells, such as chromatin 
condensation, cytoplasm contraction and DNA fragmentation70.  This caspase cascade forms part of 
the so-called extrinsic pathway of apoptosis and leads to AICD.
Figure 1.5.  The extrinsic apoptosis pathway. 
Following Fas interaction with its ligand FasL, death 
domains within the Fas cytoplasmic tail mediate FADD 
recruitment and the subsequent formation of the 
death-inducing signaling complex (DISC).  Within this 
complex, autoprocessing of pro-caspase 8 leads to the 
enzymatically active form of caspase-8, which in turn 
activates the downstream effector caspases3 and 7.  The 
cell subsequently undergoes morphological changes and 
finally, apoptosis.
1.5.2 The B6/lpr mouse model of autoimmune disease
The crucial role of Fas in T cell homeostasis and tolerance maintenance is demonstrated by 
B6/lpr mice (lpr: lymphoproliferation).  Fas deficiency due to a disruption of the fas gene (by insertion 
of a retrotransposon) causes severe defects in extrinsic apoptosis signaling and, in consequence, 
development of autoimmune disease71.  These mice have a typical phenotype characterized by 
enlarged secondary lymphoid organs (extensive lymphadenopathy and splenomegaly) due to 
accumulation of DN T cells, hypergammaglobulinemia, elevated levels of anti-DNA antibodies, immune 
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complex precipitation in kidneys and moderate glomerulonephritis72.  In addition, accumulation of 
CD4+CD44highCD62Llow memory T cells is observed73.  In lpr mice on the autoimmunity-prone MRL 
background, severity of autoimmune manifestations is increased and kidney failure leads to early 
death in MRL/lpr mice73,74.
Development of lymphadenopathy in B6/lpr mice was initially attributed to defective 
lymphocyte apoptosis71; however, defects in other elements of the apoptotic pathway (such as 
FADD or caspase -8) lead to immunodeficiency and not to autoimmunity as in B6/lpr mice75,76.  The 
resistance to apoptosis of B6/lpr T cells observed in in vitro studies also often fails to appear in 
physiological conditions72.  Another yet unexplainable observation is the T cell hyperproliferation 
detected in lymph nodes of B6/lpr mice in vivo77,78.  The autoimmune phenotype in Fas-deficient 
mice thus appears to be complex and cannot be justified only by the defect in apoptosis signaling; 
other factors might be involved to cause lupus-like disease. As several human autoimmune diseases 
present Fas deficiency and/or uncontrolled lymphoproliferation, the origin of autoimmunity in Fas-
deficient mice is currently of special interest.
1.5.3 The autoimmune lymphoproliferative syndrome
In humans, mutations in the gene that encodes Fas –and other molecules implicated in 
the extrinsic apoptosis pathway– lead to development of an autoimmune lymphoproliferative 
syndrome (ALPS)79-81.  Patients suffering from this rare disorder have defective apoptotic 
mechanisms in lymphocytes and as a result, lymphocyte accumulation and autoimmunity82.  Onset 
of lymphoproliferation and autoimmune manifestations are normally detected in early childhood, 
but can also be diagnosed in adults. The most common ALPS-associated clinical manifestation 
is increased proliferation of lymphocytes (mostly DN T cells), causing enlargement of secondary 
lymphoid organs (lymphadenopathy and splenomegaly, presented by >80-90% of patients). 
Other common features of ALPS are mild to severe autoimmunity (anti-DNA antibodies as well as 
autoimmune cytopenias, hemolytic anemia, neutropenia, and/or thrombocytopenia) and increased 
risk of secondary cancers (Hodgkin and non-Hodgkin lymphomas; carcinomas)82,83.
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1.6 The cell cycle inhibitor p21 and its implication in autoimmunity
1.6.1 Regulation of cell cycle progression
After activation by antigen encounter, T lymphocytes begin to proliferate in order to exert 
their specific effector function (clonal expansion; see 1.4.1).  During the division cycle, T cells pass 
through four distinct phases: cell growth (G1), DNA replication (S), chromosome distribution to 
daughter cells (G2) and mitosis (M).
External events, such as TCR activation, initiate the replication process, and the progression 
from one stage to the next is governed by several internal control mechanisms.  At these cell cycle 
checkpoints, different cyclins associate with cyclin-dependent kinases (CDK) to coordinate cell cycle 
events84.  Activated CDK phosphorylate and thus activate other regulatory molecules involved in cell 
cycle progression.  G1 to S phase transition is characterized by activation of cyclinD/CDK4, cyclinD/
CDK6 and cyclinE/CDK2 complexes85 (Fig. 1.6).  By phosphorylating retinoblastoma proteins (pRb), 
these cyclin/CDK complexes enable the release of E2F2 transcription factors and thus facilitate the 
transcription of genes required for cell cycle progression86.
Figure 1.6.  The G1/S checkpoint of the eukaryotic cell cycle.  CDK associate with different cyclins (cyclinD/CDK4,6 and 
cyclinE/CDK2 complexes) to promote transition from G1 to S phase, inactivating the transcriptional repression of E2F2 
transcription factors by retinoblastoma proteins (pRb).  E2F2 transcription factors subsequently induce genes required for 
cell cycle progression.  The activity of cyclinE/CDK2 complexes is repressed by CDK inhibitors p21 and p27; p16 selectively 
inhibits cyclinD/CDK4,6 complex activity.
pRb
pRb
cell cycle
        progression
E
CDK2
D
CDK4/6
phosphorylation
p21 p27
p16
E2F
E2F2A
CDK2
A/B
cdc2
S
G1
G2
G0
M
cell cycle
25
1.  INTRODUCTION
There are nonetheless various regulatory molecules that block cell cycle progression to 
restrain proliferation of activated T lymphocytes or to prevent the generation of compromised 
T cells due to DNA damage.  CDK activation is inhibited by negative regulators known as CDK 
inhibitors, which act at different checkpoints during the cell cycle.  Entry into S phase is controlled 
by two families of CDK inhibitors86; p15, p16, p18 and p19 form part of the INK4 family and bind to 
CDK4 or CDK6 to inhibit their interaction with cyclinD87, whereas the Cip/Kip family members p21, 
p27 and p57 prevent the formation of cyclinE/CDK2 complexes88.  In consequence, pRb remains 
unphosphorylated, E2F2 downstream activities are repressed and the cell cycle is arrested.  In the 
absence of p16 or p27, lymphoid organs are enlarged or lymphocyte selection in the thymus is 
impaired, but break of tolerance is not observed89-91.  In contrast, p21 deletion leads to loss of 
tolerance and autoimmunity development, indicating a specific role for p21 in cells of the immune 
system (see below).
1.6.2 The cell cycle inhibitor p21
In the early 1990s, p21 was the first molecule identified as a CDK inhibitor92 and as a p53 
effector in response to DNA damage93,94.  At present, the Cip/Kip family of cell cycle inhibitors is 
comprised of p21, p27 and p57, which act mainly at the G1 checkpoint.  By binding to CDK2 via 
specific sequences in its N-terminal domain, p21 acts as negative regulator of cyclin/CDK complex 
activity and induces cell cycle arrest in G195,96.  In addition to its most prominent role as a CDK2 
inhibitor, p21 has important functions in multiple cellular processes such as differentiation, apoptosis 
and transcription97.
One of the most important p21 functions is its implication in the cell response to DNA 
damage98.  Detection of DNA lesions leads to p53-dependent transcription of the gene CDNKN1A, 
which encodes p21.  Increased amounts of p21 then inactivate G1 phase cyclin/CDK complexes and 
halt the cell cycle to allow DNA repair97,99.  Following environmental stress, p21 is activated in a p53-
independent manner to prevent malignant cell transformation due to genomic instability.  p21 is 
also able to inhibit cell cycle progression directly.  Due to the strong affinity of its C-terminal domain 
for the polymerase co-factor PCNA (proliferating cell nuclear antigen), p21 can interrupt the PCNA 
interaction with DNA synthesis molecules and thus blocks DNA replication pathways100.
The role of p21 in regulation of programmed cell death is currently debated.  p21 might 
have pro- or anti-apoptotic functions, depending on cellular context and stress conditions, e.g., 
magnitude of DNA damage101,102.  Apoptosis is also promoted or inhibited depending on the 
subcellular localization of p21.  Within the cytoplasm, p21 interacts with caspase-2, pro-caspase-3 
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and other stress-induced MAP kinases such as ASK1 (apoptosis signal-regulating kinasex1), 
impeding their activation and thereby inhibiting apoptosis103,104, whereas nuclear localization 
favors p21 degradation and thus promotes apoptosis induction after DNA damage105.  Not only p21 
downmodulation but also its overexpression induces apoptotic signaling pathways in response to 
irradiation106-108.  Overall, p21 has a fine-tuned role in cell death regulation, although the modulating 
mechanism remains elusive109.
As p21 inhibits cell cycle progression, its absence was thought to promote cancer development. 
Nonetheless, p21-/- mice are not more tumor-prone than normal mice56,110,111.  In addition, CDKN1A is 
rarely deleted in human tumors, and p21 is usually only partially downregulated and not completely 
lost in tumor cells112.  These findings indicate that oncologic transformation of p21-deficient cells is 
caused by other elements, and suggest a tumor-suppressive role for cytoplasmicxp21.
1.6.3 p21 as suppressor of autoimmunity
To determine the role of p21 in induction of autoimmune diseases, we generated p21deficient 
mice on a neutral C57BL/6 background.  p21-/- mice develop normally, but lose tolerance to DNA over 
time and finally develop moderate, non-lethal autoimmunity including mild glomerulonephritis56. 
The appearance of the autoimmune phenotype in these mice was linked to defective homeostasis 
in effector/memory T cells and macrophage hyperactivation56,111.
In other studies, deletion of p21 in mice with a mixed background (C57BL/6 x Sv/129) led 
to severe lupus-like autoimmunity and death at less than one year of age.  Some characteristics 
observed in these mice, such as lymphadenopathy, splenomegaly, glomerulonephritis, T cell 
accumulation and high levels of anti-DNA antibodies, are similar to the phenotype presented by 
B6/lpr mice57 (see 1.5.2), although the severe disease outcome was attributed to the mixed genetic 
background enhancing the effect of p21 deletion.
Also in humans, p21 deficiency is related to autoimmune diseases.  Mutations in CDKN1A 
(which encodes p21) and other genes located on chromosome 6 (e.g., HLA class I+II and STAT4) 
were associated with SLE113-115.  These mutations are inherited in some cases, but can also appear de 
novo.  Not only genetic susceptibility, but also environmental factors are thought to be responsible 
for the occurrence of this systemic autoimmune disease116.  In general, SLE affects women at 
higher rates than men (9:1), and disease usually manifests at age 15 - 35 years.  In SLE patients, 
defective apoptosis leads to generation of anti-nuclear antibodies (ANA), subsequent precipitation 
of immune complexes, and inflammatory responses.  As a result of chronic inflammation, tissues 
of multiple organs such as skin, liver, kidney, joints, blood vessels, heart and the nervous system 
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can be damaged116.  Elevated levels of pro-inflammatory cytokines such as IL-17 were linked to 
development of lupus nephritis61.  At the cellular level, hyperproliferation of T lymphocytes due 
to altered TCR signaling117 and accumulation of DN T cells is observed61.  SLE is not currently 
curable and immunosuppressive drugs such as cyclophosphamide or corticosteroids are common 
treatments116.
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To avoid development of autoimmunity, the maintenance of T cell tolerance is fundamental 
for the organism.  This tolerance is established by the fine balance between T cell activation, 
proliferation and death, processes in which a broad variety of molecules are involved.  Their activity 
must be strictly controlled, as any dysregulation leads to severe immune defects.  One example is the 
cell cycle inhibitor p21; C57BL/6 p21-/- mice (hereafter, p21-/-) develop normally, but continuously lose 
tolerance to DNA until they finally develop mild autoimmune disease56,57.  An important characteristic 
of p21-/- mice is the hyperactivation and subsequent in vitro hyperproliferation of CD4+xmemory 
Txcells, as previously reported by our group56.  This massive proliferation was not detectable in vivo 
however; here, we established an in vitro stimulation system that approximates the results of the 
T cell responses observed in vivo.  As p21 was implicated in effector/memory Txcell activation, an 
event often dysregulated in autoimmune diseases, understanding the regulatory function of p21 is 
of considerable interest.
For the present study, the following objectives were defined:
To study the effect of p21 on T cell activation in diverse 1. in vitro systems and identify the 
activation pathways controlled by p21.
To examine whether p21 regulates T cell activation independently of its role as a cell cycle 2. 
inhibitor.
To define the influence of p21 on T cell activation in response to low affinity antigens, an 3. 
event considered critical for development of autoimmunity.
To 4. analyze the effect of p21 deficiency on T cell activation in parallel with the autoimmunity-
inducing lpr defect.
To determine the therapeutic effect of T cell-specific p21 overexpression on lupus-prone 5. 
B6/lpr mice.
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3.1 Mice
C57BL/6 mice (hereafter, B6) were obtained from Harlan Interfauna Ibérica (San Felíu de 
Codines, España).  Fas-deficient C57BL/6-lpr mice (B6/lpr) were provided by Jackson Laboratory 
(ME, USA).  C57BL/6-p21-/- mice (p21-/-) were generated by crossing p21-/- 129/Sv mice (laboratory 
of Dr. Gregory Hannon, Cold Spring Harbor Laboratory, NY, USA) with C57BL/6 mice over eight 
generations.  Background analysis via microsatellite markers confirmed >99% identity with the 
C57BL/6 background56.  C57BL/6-lpr-p21-/- mice (B6/lpr-p21-/- were generated by crossing C57BL/6-
lpr with C57BL/6-p21-/- mice.  
C57BL/6-p21tg mice (B6p21tg) were a gift from Dr. Arun Fotedar’s laboratory (Sidney Kimmel 
Cancer Center, San Diego, CA, USA)106.  C57BL/6-lpr-p21tg mice (B6/lpr-p21tg) were generated 
from C57BL/6-lpr and C57BL/6-p21tg mice by crossing for at least eight generations.  As transgene 
expression is controlled by the Lck promotor, human p21 expression is resticted to T cells in both 
C57BL/6-lpr-p21tg and C57BL/6-p21tg mice106.  
pcc.TCRtg mice express a transgenic TCR specific for pigeon cytochrome C (PCC 88-104) 
and were kindly provided by Dr. Mark M. Davis (Stanford University School of Medicine, Stanford, 
CA, USA)118.  These mice have an I-Ak haplotype and 90% of all T cells express the TCR variable 
regions Vα11 and Vβ3.  pcc.TCRtg-p21-/- mice were generated by crossing pcc.TCRtg and C57BL/6-
p21-/- for several generations, conserving the IAk haplotype.  B10BR mice present an I-Ak haplotype 
and were provided by the Jackson Laboratory.  OT-II mice (I-Ab haplotype) were also purchased from 
the Jackson Laboratory and express a transgenic TCR (Vα2) specific for chicken ovalbumin (OVA 323-
339)119,120.  p21-/- OT-II mice were generated in our laboratory by crossing OT-II and C57BL/6-p21-/- for 
several generations, conserving the I-Ak haplotype.
All strains were maintained at the CNB animal facility in pathogen-free conditions.  Unless 
otherwise specified, mice were approximately 8-10 weeks old when used for experiments.  All 
animal experiments complied with European regulations and were approved by the CNB Bioethics 
Committee.
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3.2 Cell culture
3.2.1 Isolation of CD4+ T cells
To obtain a single-cell suspension, spleens were segregated using 40 µm nylon filters 
(BD Biosciences) with RPMI-1640 medium (Gibco Life Technologies) containing HEPES (10 mM). 
Erythrocytes were subsequently lysed by treatment with an ammonium chloride solution 
(0.83%xNH
4
Cl, 0.1% KHCO3 and 0.004% EDTA [ethylenediaminetetraacetic acid]) for 4 min at RT 
(room temperature).  For isolation of CD4+ T cells by negative selection, the cell suspension was 
incubated with magnetic beads coated with anti-CD8 and -B220 antibodies (pan-B220 and anti-CD8 
Dynabeads; Dynal Biotech, Invitrogen) for 40 min at 4ºC with gentle shaking.  A magnetic field was 
then applied and the supernatant (containing CD4+ cells) was separated. The purity of CD4+ cells was 
confirmed by flow cytometry and was routinely >80%.
3.2.2 Cell culture medium
Purified CD4+ T cells were cultured in RPMI-1640 medium supplemented with 10% FCS 
(fetal calf serum; Harlan Bioproducts, SeraLab), 2 mM Lglutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 1 mM sodium pyruvate, 10 mM HEPES pH 7.4, 0.1 mM nonessential amino acids and 
50 mM β-mercaptoethanol (all from Gibco Life Technologies).
3.2.3 Repeated in vitro stimulation protocol
For primary stimulation, previously purified CD4+ T cells were plated (1 x 106 cells/ml) 
and stimulated with 1.5 μg/ml concanavalin A (ConA; Sigma Aldrich) in the presence of human 
recombinant interleukin-2 (hrIL-2; 20 ng/ml; PeproTech) for 24 h in vitro.  Cells were washed and 
replated in fresh RPMI medium (0.5 x 106 cells/ml) supplemented with 20 ng/ml hrIL-2 for a total 
of 6 days; medium was changed after 3 days to prevent nutrient and IL-2 depletion.  After this IL-2 
expansion phase, cells were restimulated with ConA (1.5 μg/ml) for the indicated time (secondary 
stimulation).  As rechallenge of CD4+ T cells with the same antigen induces AICD, secondary 
stimulation was usually carried out with the apoptosis inhibitor zVAD (benzyloxycarbonyl-Val-Ala-
Asp-fluoromethlketone; Bachem) at indicated concentrations121.
In some experiments, cells were stimulated with PMA (phorbol 12-myristate 13acetate, 
20 ng/ml; Calbiochem) and ionomycin (0.5 μg/ml; Sigma), with plate-bound anti-CD3 
(0.5 μg/ml; PharMingen) in 0.1 M Tris-HCl and soluble anti-CD28 (1 μg/ml; PharMingen) or with 
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IL-12 (10 μg/ml) and IL-18 (10 μg/ml; both from Sigma Aldrich).  Some cell cultures were carried 
out in the presence of different inhibitors, such as the inhibitor of ERK1/2 phosphorylation, U0126 
(1,4-diamino-2,3-dicyano-1,4-bis[2- aminophenylthio] butadiene; Cell Signaling) at 10 mM final 
concentration122, the inhibitor of IκBα phosphorylation BAY11-7082 ((E)-3-(4-methylphenylsulfonyl)-2-
propenenitrile, Sigma Aldrich) at 10 mM final concentration123, or the inhibitor of CDK2 activation 
CVT-313 (CDK2 inhibitor III; Calbiochem) at 2.5 mM final concentration124,125.
Figure 3.1.  Repeated in vitro stimulation protocol.  CD4+ cells isolated from murine spleens were stimulated for 24 h with 
ConA (1.5 μg/ml), expanded for 6 days in hrIL-2 (20 ng/ml), and restimulated under varying conditions.  To avoid AICD, 
secondary stimulation was carried out in the presence of zVAD (12.5 mM).
3.2.4 Generation of bone marrow-derived dendritic cells
Bone marrow extracted from mouse femur and tibia was segregated using 40 µm nylon 
filters (BD Biosciences) in RPMI-1640 medium containing HEPES (10 mM).  After erythrocyte lysis, 
bone marrow progenitor cells were cultured with GM-CSF (granulocyte/macrophage colony-
stimulating factor; 20 ng/ml) to promote DC differentiation and proliferation.  GM-CSF was obtained 
from supernatant of the melanoma tumor D5-G6 cell line (a kind gift of Dr. Abul Abbas, Universidad 
de California, San Francisco, CA, USA).  After three days, fresh medium and GM-CSF (20 ng/ml) were 
added.  At day 6, slightly attached cells were lifted with 3 mM EDTA in 1x PBS (1 min) and, together 
with non-adherent cells (supernatant), washed and transferred to new plates.  In addition to GM-
CSF (20 ng/ml), IL-4 (1 ng/ml), generated from supernatant of I3L6 cells (a kind gift of Dr. Abul 
Abbas), was added to the cell culture.  The next day, 1 mg/ml LPS (lipopolysaccharide, Escherichia 
coli O26:B6; Sigma Aldrich) and 1 mM peptide (ovalbumin, OVA 323-339) were added to promote 
DC maturation and protein presentation.  After 20 h, non-adherent cells were collected and stained 
for CD86 (B72) and I-Ab (MHC II) to test the yield of DC by flow cytometry (normally >60%).
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3.2.5 Mixed cultures of pcc.TCRtg CD4+ T cells with APC
To stimulate CD4+ T cells in more physiological conditions, APC were used to present agonist 
peptides with high (PCC, KAERADLIAYLKQATAK) or low affinity (A96I, KAERADLIIYLKQATAK; isoleucine 
replaced alanine at position 96 of the PCC peptide)126,127 for the transgenic TCR of naïve CD4+ T cells 
isolated from spleens of pcc.TCRtg or pcc.TCRtg-p21-/- mice (see 3.2.1).  APC were obtained from 
B10BR mice by segregation of spleens on 40 µM nylon filters and subsequent lysis of erythrocytes 
(described in 3.2.1).  Finally, APC were irradiated at 30 Gy to prevent proliferation during culture. 
For the first stimulation, CD4+ TCRtg T cells (0.5 x 106 cells/ml) were plated at a 1:3 ratio with 
irradiated APC.  As naïve CD4+ T cells show less affinity to MHC II molecules presenting peptides than 
memory T cells128, an agonist peptide with high affinity for the TCR (PCC; 3 mM) was used to stimulate 
naïve CD4+ TCRtg T cells in the presence of hrIL-2 (20 ng/ml).  After 24 h, cells were washed and 
replated at a final concentration of 0.5 x 106 cells/ml in fresh RPMI medium supplemented with 
hrIL-2 (20xng/ml) for a total of 6 days.  Medium was changed every 2 days to avoid nutrient and 
hrIL2 depletion.  After this expansion phase, cells were washed and restimulated with irradiated 
APC (1:3 ratio of 1 x 106 CD4+ TCRtg T cells/ml to APC).  For the secondary stimulation, different 
concentrations of agonist peptides with high or low affinity for the TCR were used (PCC or A96I) in 
the presence of hrIL-2.      (20 ng/ml) and zVAD (12.5 mM) (Fig. 3.2).
Figure 3.2.  In vitro system of repeated stimulation of pcc.TCRtg and pcc.TCRtg-p21-/- CD4+ T cells with irradiated APC, 
presenting peptides with high or low affinity for the TCR.
3.2.6 Mixed cultures of OT-II CD4+ T cells with DC
Similar to the mixed cell cultures of pcc.TCRtg T cells (3.2.5), purified naïve OT-II and 
p21-/- OT II CD4+ T cells were stimulated with their specific peptide (OVA 323-339)119,120, in this case 
presented by DC obtained from C75BL/6 mice (see 3.2.4).  After 24 h primary stimulation with DC 
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presenting OVA (CD4+:DC ratio 10:1), CD4+ T cells were expanded in hrIL-2 (20 ng/ml) for a total 
of 6 days and subsequently restimulated with OVA-loaded DC (in conditions as for the primary 
stimulation) for the indicated times in the presence of zVAD (12.5 mM) (Fig.3.3).
Figure 3.3.  In vitro system of repeated stimulation of OT-II and p21-/- OT-II CD4+ T cells with DC presenting OVA 
peptide.
3.3 Adoptive transfer of OT-II CD4+ T cells
Purified naïve OT-II and p21-/- OT-II CD4+ T cells were CFSE (carboxyfluorescein succinimidyl 
ester; Molecular Probes)-labeled (see 3.5.2) and adoptively transferred (1 x 106 CD4+ T cells/mouse) 
to recipient mice of the same haplotype (B6).  After 24 h, OVA-loaded DC were injected to stimulate 
the previously transferred CD4+ TCRtg T cells in vivo.  After 3 days, mice were sacrificed and cells 
from secondary lymphoid organs were analyzed or restimulated ex vivo with 1 mM OVA for the 
indicated times (Fig. 3.4)129.
Figure 3.4.  Adoptive transfer of TCRtg CD4+ T cells.  Purified OT-II and p21-/- OT-II CD4+ (Vα2+) were injected into C57BL/6 
recipient mice (1 x 106 cells/mouse), followed 24 h later by injection of DC presenting OVA peptide (1 x 106 cells/mouse). 
After 3 days, mice were sacrificed, and T lymphocytes obtained from spleens and lymph nodes were analyzed or 
restimulated ex vivo.
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3.4 Flow cytometry (fluorescence-activated cell sorting, FACS)
3.4.1 Extracellular staining
For extracellular staining, 0.5-1 x 106 cells were harvested into FACS tubes and incubated 
with 30 µl of different antibody mixtures depending on the experiment, for 20 min at 4ºC in the 
dark.  Antibodies were diluted following the manufacturer’s instructions in staining PBS (1x PBS, 
5% FCS, 1% BSA, 5 mM EDTA).  Cells were then washed with 1 ml staining PBS, resuspended in 
300 μl of staining PBS and analyzed on a cytometer (FC 500 or Gallios; Beckman Coulter).
The following antibodies were used routinely for extracellular staining: anti-B220-APC, 
-CD4-FITC, -CD4-SPRD, -CD8-PE, -CD44-FITC (all from Beckman Coulter), -CD4-PeCy7, CD62LAPC, 
-CD69-FITC (all from eBioscience), -B7-2-PE (CD86), -CD25-FITC, -CD69-PE, TCRβFITC, Vα2-PE, -Vβ3-
FITC, -Vβ3-PE (all from PharMingen) and -I-Ak-FITC (Serotec).
For further analysis, FlowJo software was used (Tree Star, Inc.; version 8.8.3).
3.4.2 Intracellular cytokine staining
For intracellular cytokine staining, cells were isolated from murine spleens, plated 
(5xxx106xcells/ml) and stimulated (1 h, 37ºC) in culture medium containing PMA (50 ng/ml) and 
ionomycin   (2 μg/ml).  Brefeldin A (GolgiPlug, 2 mg/ml; BD Pharmingen) was added and cells were 
incubated for an additional 3 h at 37ºC.  After surface marker staining (CD4, CD8, CD44, CD62L), 
cells were washed with staining PBS, fixed, and permeabilized with 100 μl Cytofix/Cytoperm 
(Cytofix/Cytoperm-Fixation/Permeabilization kit, BD Biosciences) at 4ºC for 20 min.  Cells were 
then washed with 1x Perm/Wash buffer and stained with anti-IFNγ-APC, IL-17-APC and -IL-2-APC 
antibodies (1/100; all from PharMingen).  After incubation (30 min, 4ºC), cells were washed twice 
with 1xxPerm/Wash before FACS analysis.
3.5 In vitro proliferation assays
3.5.1 [3H] thymidine incorporation
Cells were cultured in 96-well plates (1 x 106 cells/ml) for indicated times, with addition 
of  [3H] thymidine (1 µCi/well; Perkin Elmer) during the last 16 h of culture.  To measure T cell 
proliferation, cell fragments were transferred onto fiber filters (Wallac) using a semi-automatic cell 
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harvester (Wallac) and [3H] thymidine uptake was quantified by a beta-plate counter (b1205 Wallac, 
Perkin Elmer).  Incorporation of [3H] thymidine into DNA is proportional to DNA synthesis.
3.5.2 CFSE fluorescence dilution assay
CFSE is a fluorescent dye for intracellular proteins bearing amino groups.  After cell division, 
the label is inherited by daughter cells and thus can be used to monitor proliferation over time130.
For intracellular staining, T cells were resuspended in prewarmed 1x PBS + 0.1% BSA at 
a final concentration of 1 x 106 cells/ml and incubated with 2.5 μM CFSE for 45 min at 37ºC. The 
reaction was terminated by incubating cells on ice for 10 min.  Cells were then washed three times 
with cold RPMI-1640 medium and stimulated according to the requirements of each experiment 
(1xxx106xcells/ml).  CFSE fluorescence decay at the indicated times was measured by flow cytometry, 
gating on live PI (propidium iodide)-negative cells.  A decrease in CFSE fluorescence intensity 
correlates with number of cell divisions.
In some experiments, CD4+ TCRtg cells were CFSE-labeled before injection or stimulation 
with APC in vitro (see 3.2.5-7).
3.5.3 Cell cycle analysis
To analyze the different phases of the cell cycle at indicated time points, 0.5-1 x 106 cells were 
harvested into FACS tubes and permeabilized by incubation with 50 µl detergent. DNA was stained 
with 400 µl of PI (10 mg/ml; both reagents from the DNA-Prep Reagent Kit, Beckman Coulter) for 
30 min at 37ºC.  In some experiments, cells were fixed with 70% EtOH (20ºC, overnight).  The next 
day, cells were washed with 1x PBS, incubated with 400 µl PI (30 min, 37ºC) and analyzed by flow 
cytometry (FC500, Beckman Coulter).
To analyze cell cycle profiles within specific T cell subsets, extracellular staining was performed 
prior to permeabilization in some experiments (see 3.3.1).  Cells were then stained with 2 µg DAPI 
(4’,6-diamidino-2-phenylindole) diluted in staining PBS (30 min, 37ºC) and analyzed directly by flow 
cytometry (Gallios, Beckman Coulter).
3.5.4 In vitro BrdU assay
Cells were plated at 1 x 106 cells/ml and stimulated depending on experimental needs 
(usually 24 h).  For the last 3 h of cell culture, 20 mM BrdU (5-bromo-2´deoxyuridine, Sigma Aldrich) 
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was added to the culture.  BrdU is a thymidine analogue and is incorporated into the DNA of 
proliferating cells131.  After harvesting the cells, extracellular staining was performed (see 3.3.1) 
to monitor proliferation in different T cell subsets.  Cells were then permeabilized in 0.15 M NaCl 
+ 95% EtOH and stored at -20ºC overnight.  The next day, cells were washed and treated with fixing 
buffer (1x PBS, 1% paraformaldehyde and 1% Tween20) for 30 min at RT and another 30 min at 
4ºC.  DNA was digested with DNase I (100 U/ml, Roche) diluted in 0.15 M NaCl, 4.2 mM MgCl and 
10 mMxHCl for exactly 10 min at RT.  After several washing steps, BrdU was used for intracellular 
staining, incubating each sample with 10 μl anti-BrdU-FITC for 1 h at RT (see 3.4.2).  Cells were 
washed with staining PBS prior to FACS analysis (Gallios, Beckman Coulter).
3.6 In vivo BrdU administration
T cell proliferation in physiological conditions was analyzed in an in vivo BrdU incorporation 
assay.  BrdU was administered orally to the mice via drinking water (0.8 mg BrdU/ml) for a total of 
9 days (renewing the solution every 2 days).  After sacrificing the mice, T cell populations of spleens 
and lymph nodes were analyzed as described in 3.5.4.
3.7 Calcium (Ca2+) mobilization assay
Cells were harvested, washed with 1x PBS and resuspended in medium containing 
10% FCS  (2.5 x 106 cells/ml).  After addition of 7 μl Fluo-3 AM (250 μM stock solution in DMSO 
(dimethylsulfoxide)), cells were incubated at 37ºC for 30 min.  Cells were then washed and 
resuspended in complete medium (see 3.3.2) containing 2 mM CaCl2 (0.5 x 10
6 cells/ml).  Prior 
to FACS analysis (Epics XL-MCL, Beckman Coulter), cells were incubated at 37ºC for 5 min.  After 
establishing the baseline, cells were stimulated with 5 μg/ml anti-CD3 and 1 μg/ml anti-CD28 
antibodies.  For direct store depletion, 1 μg/μl ionomycin was added.
3.8 Protein biochemistry
3.8.1 Western blot
Protein lysates of cultured cells (5 x 106 cells/sample) were obtained by lysis of CD4+ 
T cells for 20 min on ice using a 0.2% NP-40 lysis buffer (10 mM TrisHCl pH 7.5, 150 mM NaCl, 
0.2% NP40) supplemented with Phosphatase Inhibitor Cocktail (PhosStop) and Complete Protease 
Inhibitor Cocktail (both from Roche).  After quantification of protein concentration by Bradford 
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assay (Bio-Rad), equal protein amounts (5-15 μg) were separated on 12% acrylamide gels and 
transferred to a nitrocellulose membrane (BioRad).  Membranes were blocked in 5% low fat milk 
(1x TBS + 0.05%xTween20) and incubated with primary antibody dilutions as recommended by the 
manufacturer.  Primary antibodies were purchased from Cell Signaling (anti-pERK, -ERK, -histone 
H3), Santa Cruz Biotechnology (anti-p21, -CDK2) or Sigma (anti-β-actin).  After incubation with 
appropriate peroxidase-conjugated secondary antibodies (all from Dako), proteins of interest were 
detected by chemiluminescence (ECL, Perkin Elmer) on X-ray film (Kodak Minolta).
3.8.2 CDK2 kinase activity assay
T cells (10 x 106 cells/sample) were lysed for 15 min on ice in 250 μl lysis buffer 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM NaF, 100 mM orthovanadate, 0.5% NP50, 1x protease 
inhibitor cocktail [Roche]).  After centrifugation (10 min, 4ºC, maximum speed), protein concentration 
of supernatants was quantified by Bradford assay.  Protein (70-150 μg/sample) was precleared by 
incubation with 25 μl protein G Sepharose beads (Invitrogen).  For immunoprecipitation of CDK2, 
precleared cell lysates were incubated with 7.5 μl anti-CDK2 antibody (clone sc-163, Santa Cruz 
Biotechnology) overnight at 4ºC with rotation.  In addition, 25 μl protein G Sepharose beads per 
sample were blocked in 3% milk + lysis buffer for 1 h at 4ºC, washed with lysis buffer and stored at 
4ºC overnight.
The next day, 25 μl blocked Sepharose beads were added to each sample, and incubation 
continued for another 2 h.  CDK2 proteins attached to beads were then washed 2x with lysis 
buffer and 2x with kinase buffer (20 mM Tris-HCl pH 8, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 
1 mM NaF, 1 mM orthovanadate, 1x protease inhibitor cocktail).  Sepharose-coupled CDK2 (10 μl), 
20 μl kinase buffer, 0.5 mM adenosine triphosphate (ATP) and 10 μCi [γ32P]-ATP (3000 Ci/mmol, 
10 mCi/mL; Perkin Elmer) were incubated with 5 μg histone H1 (Boehringer) as substrate for CDK2 
at 30ºC for  30 min.  Samples were resolved by 15% SDS-PAGE, blotted on nitrocellulose membranes 
and visualized by autoradiography.  To confirm loading and total amount of CDK2 in each sample, 
Western blot analysis of total cell lysates was performed (see 3.7.1).
3.8.3 Electrophoretic mobility shift assay (EMSA)
For cell lysis, pellets (10 x 106 cells per sample) were defrosted on ice and resuspended 
in 500μl buffer A (10 mM Hepes pH 8, 50 mM NaCl, 0.2 mM saccharose, 1 mM EDTA, 0.5 mM 
spermidine, 0.15 mM spermine, 0.5% Triton X100, 1 mM PMSF, 2 ng/μl aprotinin, 0.5 ng/μl 
pepstatin, 7 mM β-mercaptoethanol).  After incubation on ice for 5 min, cells were centrifuged and 
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the supernatant (cytosolic fraction) was separated.  The pellet, containing nuclei, was washed with 
300 μl of buffer B (10 mM Hepes pH8, 50 mM NaCl, 0.1 mM EDTA, 25% glycerol, 1 mM PMSF, 2 ng/μl 
aprotinin, 0.5 ng/μl pepstatin, 7 mM βmercaptoethanol) without resuspending.  After centrifuging, 
the supernatant was discarded and the pellet was resuspended in 60 μl of buffer C (10 mM Hepes 
pH8, 350 mM NaCl, 0.1 mM EDTA, 0.5 mM spermidine, 0.15 mM spermine, 25% glycerol, 1 mM 
PMSF, 2 ng/μl aprotinin, 1 ng/μl pepstatin, 7 mM β-mercaptoethanol) and incubated on ice for 
30 min to obtain nuclear lysates.  Protein concentration was determined by Bradford assay, and 
aliquots were stored at 80ºC. Radioactive labeling of double-stranded probes (200 ng) was carried 
out in 10x T4 kinase buffer and catalyzed by T4-polynucleotide kinase (30 min, 37°C).
Equal amounts of nuclear protein extracts (4-7 μl) were incubated with binding buffer 
(37.5 mM Hepes, 0.25 mM EDTA, 5 mM MgCl2, 1.75 M NaCl, 2.5 mM DTT (dithiothreitol), 
43.1% glycerol), 1.4 μl poly(dI-dC) and 1 μl [γ-32P]-ATP-labeled probe containing the required 
transcription factor consensus sequence (NF-κB: 5´AGTTGAGGGGACTTTCCCAGGC-3´, Promega; 
AP-1: 5´-CGCTTGATGAGTCAGCCGGAA-3´, Promega; NFAT: 5´-GCGCCAAAGAGGAAAATTTGTTTCATA-3´, 
Santa Cruz Biotechnology) to analyze DNA-protein interactions.  After incubation for 20 min at 25ºC 
(with shaking), samples were resolved on a 5% acrylamide gel in 0.5x TBE buffer.  Gels were then 
dried and exposed to X-ray film (Kodak Minolta) at -80ºC for up to 17 h.  A probe containing the NF-Y 
consensus sequence was used as loading control.
3.9 Confocal microscopy
For secondary stimulation, cells were cultured on collagen-I-covered chamber slides (Lab-
Tek) and stimulated with 1.5 μg/ml ConA, 20 ng/ml hrIL-2 and 50 μM zVAD (24 h, 37ºC).  To terminate 
stimulation, cells were incubated at 4ºC, fixed, and permabilized with Cytofix/Cytoperm solution 
(BD Biosciences; 30 min, 4ºC).  After washing twice with 1x Perm/Wash solution (BD Biosciences), 
cells were incubated with blocking solution (1x PBS + 1% BSA + 10% goat serum; 45 min, RT) in 
a humidified chamber.  Cells were then washed with 1x Perm/Wash solution and incubated with 
anti-phospho-ERK1/2 (Cell Signaling) and -p21 antibodies (Santa Cruz Biotechnology) for 45 min 
at RT in a humidified chamber.  Cells were washed three times with 1x PBS to remove unbound 
primary antibody; anti-goat IgG (Santa Cruz Biotechnology) and -rabbit IgG (Molecular Probes) 
secondary antibodies were added (1 h, RT).  After mounting cells in DAPI-containing mounting 
medium (Vectashield; Vector Laboratories), fluorescence was documented on a confocal microscope 
(Olympus).
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3.10 Serological and histological analysis
3.10.1 Kidney cryosections and glomerulonephritis evaluation
Kidneys were isolated and incubated in fixing solution prior to embedding in paraffin 
blocks.  Cryosections were prepared by the CNB Histology Facility, and glomerulonephritis grade 
was evaluated by Dr. Juana Flores, Animal Biology Department, School of Veterinary Medicine 
(Universidad Complutense de Madrid, Spain) according to the following scale132: (0) no glomerular 
lesions, (I) minimal mesangial lupus nephritis with mesangial accumulation of immune complexes, 
(II) mesangial proliferative lupus nephritis with increases in mesangial and glomerular cellularity, 
(III) focal lupus nephritis characterized by segmental endocapillary proliferative lesions and 
subendothelial immune deposits, and (IV) diffuse segmental or global lupus nephritis characterized 
by segmental or global glomerulonephritis in >50% of all glomeruli and diffuse subendothelial 
immune deposits.
3.10.2 Cytokine quantification in cell culture supernatants or serum
For analysis of IL-2, IL-17 and IFNγ cytokine secretion levels, cell culture supernatants or 
sera were collected and incubated with microbeads specific for each cytokine (kit from Milliplex 
Mouse Cytokine/Chemokine Immunoassay, Millipore).  Samples were analyzed in duplicate by 
Luminexx100xIS.
3.10.3 Protein quantification in urine samples
For determination of protein levels in urine of 9-month-old mice (or older), Urispec 
GP+Axstips (Henry Schein, Port Washington, NY, USA) were used as indicated by the manufacturer.
3.11 Statistical analysis
Values shown represent mean ± SD, where applicable.  Statistical significance was calculated 
with the Student’s t test.  Differences were considered significant for p <0 .05 and are represented as 
*** p <0.001, ** p <0.01 and * p <0.05.
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4.1 p21 is involved in activation of CD4+ memory T cells
In the first part of the present study, p21-deficient mice on the autoimmunity-free C57BL/6 
background were used define the role of p21 in immune responses of T lymphocytes and induction 
of autoimmunity.  Several studies with mixed background (C57BL/6 x 129xSv) p21-/- mice showed 
that p21 is crucial for the maintenance of tolerance, as these mice develop acute lupus-like disease 
that leads to death in most cases57.  Lupus is caused by a combination of genetic and environmental 
factors.  The mixed genetic background, which predisposes to autoimmunity57, therefore enhances 
the outcome of the autoimmune manifestations in the absence of p21.  The C57BL/6 p21-/- model 
allows us to study the role of p21 independently and to avoid background interference with data 
interpretation.  As described in section 1.6.2, C57BL/6 p21-/- mice (p21-/-) develop normally, but 
continuously lose tolerance to DNA until they finally develop mild autoimmune disease56,57.  Age-
matched C57BL/6 (B6) mice were used as controls for this part of the study.
4.1.1 p21 expression and function during primary stimulation of naïve T cells
To mimic the in vivo situation of continuous TCR challenge by specific auto-antigens in 
autoreactive T cells, a repeated stimulation system was used in the in vitro section of this study.  For 
this purpose, purified naïve CD4+ splenocytes were activated with ConA in a TCR-dependent manner 
(first stimulation).  The CD4+ T cells were subsequently expanded in the presence of hrIL-2 for a total 
of 6 days (IL-2 expansion phase) before they were restimulated with ConA (second stimulation) 
(for details see 3.2.3).  After two successive TCR stimulations in vitro, cells were considered to be 
effector/memory T cells (CD44high), presenting an effector (CD44highCD62lhigh) or memory phenotype 
(CD44highCD62low).
In a previous study, naïve B6 and p21-/- CD4+ T cells were stimulated for 3 days prior to the 
IL-2 expansion phase, to examine the p21 effect on memory T cells56.  Applying this methodology, 
we found p21-deficient effector/memory T cells to be overactivated, resulting in their extreme 
proliferation. These findings were not entirely reflected in a physiological situation, however, as 
this massive proliferation was not detectable in vivo.  We thus considered the in vitro conditions 
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to be too vigorous, leading to overstimulation of T cells.  Our objective was thus to develop an in 
vitro stimulation system that approximates the results observed in the in vivo T cell responses.  We 
first reviewed the p21 expression pattern during primary stimulation of naïve CD4+ T cells.  Western 
blot analysis revealed that p21 is not expressed until 48 h after stimulation in naïve B6 CD4+ T cells 
(Fig. 1A).  As p21 is a direct inhibitor of the cell cycle regulator CDK2, we analyzed the activity of 
this kinase after stimulating naïve CD4+ T cells, and observed comparable activation levels in B6 and 
p21-/- CD4+ T cells until 48 h (Fig. 4.1B). Less CDK2 activity was observed in B6 CD4+ T cells at 72 h 
after stimulation, probably due to expression of its inhibitor p21 after 48 h.  In the absence of p21, 
CDK2 activity cannot be controlled and thus reached higher activation levels in p21-/- CD4+ T cells 
(Fig. 4.1B).
These results led to the final study design of stimulating primary T cells only for 1 day (24 h), 
while the rest of the protocol remained the same (see Fig. 4.4A).  In this way, we avoided possible 
interference by differential p21 expression during the initial stimulation phase, and both B6 and 
p21-/- CD4+ T cells can be cultured in equivalent conditions until the secondary stimulation.  By 
shortening the first stimulation, we also avoided possible restimulation of the same cells during 
this cell culture phase.  Compared to our previous system, we considered this methodology a 
physiologically relevant protocol for in vitro studies.
Figure 4.1.  Late expression of p21 controls CDK2 activity in naïve T cells.  A. Western blot showing endogenous p21 
expression at indicated times after first stimulation of naïve B6 and p21-/- CD4+ T cells.  β-actin was used as a loading 
control.  B. Kinetics of CDK2 kinase activity in naïve B6 and p21-/- CD4+ T cells during first ConA stimulation.  Histone H1 
was used as substrate for the kinase assay.  Total expression of CDK2 and β-actin was analyzed by Western blot and served 
as control.  Representative experiments are shown (n = 2).
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4.1.1.1 p21 deletion does not affect activation of naïve CD4+ T cells
To determine the role of p21 in the activation of naïve T cells, we compared the activation 
state of purified naïve B6 and p21-/- CD4+ splenocytes at 24 h after primary TCR challenge, and 
detected no differences in expression levels of surface activation markers such as CD69 or CD25 
(Fig. 4.2A).  In addition, we used phosphorylated ERK1/2 (phospho-ERK1/2) as an intracellular 
indicator of the T cell activation state and observed a similar pattern for ERK1/2 phosphorylation 
up to 48 h after primary stimulation (Fig. 4.2B).  These results indicate that lack of p21 does not 
influence activation of naïve T cells at 24 h after the first stimulation.
Figure 4.2. Activation of naïve CD4+ T cells after primary TCR stimulation.  A. Surface expression of CD25 and CD69 
activation markers on naïve B6 and p21-/- CD4+ T cells stimulated for 24 h with ConA, as determined by flow cytometry. 
Representative histograms are shown (n = 2).  B. ERK1/2 phosphorylation in naïve B6 and p21-/- CD4+ T cells was detected 
by Western blot at indicated times after primary stimulation with ConA.  Total ERK1/2 and βactin expression were used as 
loading controls.  A representative experiment is shown (n = 2).
4.1.1.2 Absence of p21 does not affect proliferation of naïve CD4+ T cells
As T cell activation results in proliferation, we analyzed proliferation rates of naïve B6 and 
p21-/- CD4+ T cells following TCR challenge.  After 24 h of primary stimulation with ConA, cell cycle 
profiles of naïve CD4+ T cells showed no differences in proliferation or apoptosis (Fig. 4.3A).  [3H] 
thymidine incorporation confirmed similar proliferation rates of B6 and p21-/- CD4+ T cells (Fig. 4.3B). 
TCR-specific stimulation with anti-CD3/CD28 antibodies gave results similar to those observed after 
ConA stimulation (Fig. 4.3C,D), which verified ConA as a representative TCR-stimulating agent in 
our system.  Finally, CFSE dilution assay showed the same number of cell divisions in both cell types 
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after primary stimulation (Fig. 4.3C), suggesting that lack of p21 does not influence proliferation of 
naïve T cells after primary TCR challenge.
Figure 4.3.  Similar proliferative response of naïve B6 and p21-/- CD4+ T cells to primary TCR challenge.  A,C. Cell cycle 
analysis of B6 and p21-/- CD4+ T cells at 24 h after primary stimulation with ConA (A) or with anti-CD3/CD28 antibodies 
(C).  Representative histograms are shown (ConA: n = 6; anti-CD3/CD28: n = 2).  B,D. Proliferation rates of B6 and p21-/- 
CD4+cT cells were detected by [3H] thymidine incorporation at 24 h after primary TCR challenge with ConA (B) or with 
anti-CD3/CD28 antibodies (D).  Values show mean ± SD (B: n = 3, p = 0.449; D: n = 2, p = 0.563).  E. CFSE dilution of gated 
live (PI-) naïve WT and p21-/- CD4+ T cells at 24 and 48 h after first ConA stimulation.  Representative histograms are shown 
(n = 3).
4.1.2 The role of p21 in activation of memory-phenotype T cells after secondary TCR challenge
4.1.2.1 Differential expression of p21 in effector/memoryT cells
To analyze the behavior of B6 and p21-/- memory CD4+ T cells after secondary stimulation 
in vitro, we used the repeated stimulation system (described in 4.1.1) (Fig. 4.4A).  In this step of the 
culture process, a large number of cells undergo AICD.  To obtain clearer results regarding the role 
of p21 in T cell activation, we complemented the culture with the caspase inhibitor zVAD (Z-Val-Ala-
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DL-Asp-fluoromethylketone)121.  In apoptosis-free conditions, p21 was clearly expressed in memory-
phenotype T cells even before 4 h post-TCR challenge (Fig. 4.4B).  Compared to naïve B6 T cells, 
in which p21 was not detectable before 48 h (Fig. 4.1A), effector/memory T cells expressed p21 
shortly after TCR stimulation.
Figure 4.4.  p21 is expressed early in memory-like T cells after secondary TCR challenge.  A. CD4+ splenocytes were 
isolated, ConA-stimulated for 24 h, expanded in hrIL-2 for 6 days and restimulated for the indicated times in minimal 
cell death conditions (zVAD concentrations indicated).  B. Western blot showing endogenous p21 expression in B6 and 
p21-/- CD4+ effector/memory T cells after secondary stimulation.  β-actin was used as a loading control.  A representative 
experiment is shown (n = 2).
4.1.2.2 p21-deficient memory-like T cells are hyperactivated after secondary stimulation
Effector/memory T cells that lack p21 accumulate and hyperproliferate in culture conditions 
similar to the in vitro system used in this thesis56, suggesting an additional role of the cell cycle 
inhibitor p21 in effector/memory T cell activation. In accordance with these data, we observed 
elevated surface CD69 expression levels in p21-/- CD4+ T cells after secondary TCR challenge (Figx4.5A). 
As the MAPK pathway is an important activation pathway in lymphocytes, we analyzed the ERK1/2 
phosphorylation pattern and found sustained hyperphosphorylation of ERK1/2 in p21-/- effector/
memory T cells at short (12 h) as well as at late time points (14-24 h) after repeated stimulation 
(Figx4.5B).
The transcription factor AP-1, an important downstream effector of the MAPK pathway, is 
activated by phospho-ERK1/2 and induces –together with other transcription factors– the production 
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of pro-inflammatory cytokines in response to T cell activation.  After 24 h secondary stimulation in 
vitro, restimulated p21-deficient CD4+ T cells showed higher AP1 activity levels (Fig. 4.5C), confirming 
the finding that early p21 expression controls activation events in effector/memory T cells.
Figure 4.5.  Early p21 expression after TCR stimulation controls early activation events in effector/memory T cells.  A. CD4 
and CD69 double staining at 48 h after secondary stimulation of B6 and p21-/- CD4+ effector/memory T cells.  Representative 
histograms are shown (n = 2).  B. Differential ERK1/2 phosphorylation in B6 and p21-/- CD4+ effector/memory T cells was 
detected by Western blot at indicated times after secondary TCR challenge (+ 50 μM zVAD).  Total ERK1/2 and β-actin 
were used as loading controls.  A representative experiment is shown (n = 4).  C. Electrophoretic mobility shift assay 
(EMSA) detected AP-1 activity in B6 and p21-/- effector/memory T cells after secondary ConA stimulation in the presence 
of zVAD (50 μM).  A probe containing the NF-Y consensus sequence was used as a control for sample quality in all EMSA. 
A representative experiment is shown (n = 2).  D. Intracellular staining for IFNγ in B6 and p21-/- CD4+CD44highCD62Llow T cells 
after secondary stimulation with PMA (40 ng/ml) and ionomycin (1 μg/ml) for 4 h (1 x 106 cells/ml) in vitro (top panel) and 
in splenocytes isolated from 1year-old B6 and p21-/- mice (bottom panel).  A representative experiment is shown (n = 2). 
E. Amount of proinflammatory cytokines IL-17 and IL-2 (pg/ml) measured by Luminex in cell culture supernatants of B6 
and p21-/- CD4+ T cells at 24 h after secondary TCR challenge with ConA (n = 2).
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The data showing higher ERK1/2 phosphoryation and AP-1 activation in the absence of p21 
suggested possible induction of cytokine expression in p21-/- T cells.  Indeed, we detected elevated 
intracellular expression of the pro-inflammatory cytokine IFNγ in p21-/- CD4+ T cells in vitro (Fig. 4.5D, 
top panels).  In freshly isolated splenocytes from 1-year-old mice, the difference was even more 
evident (Fig. 4.5D, bottom panels).  Larger amounts of IL-17 (B6, 243.1 pg/ml vs. p21-/-, 298.6 pg/ml) 
and IL-2 (B6, 1478.6 pg/ml vs. p21-/-, 2116.9 pg/ml) were also measured in cell culture supernatants 
of effector/memory T cells at 24 h after secondary stimulation (Fig. 4.5E).
Overall, these data support the hypothesis that lack of p21 leads to increased T cell 
activation and indicate indirectly that p21 modulates T cell activation via ERK1/2 phosphorylation. 
Whether p21 controls inflammatory cytokine expression by activated effector/memory T cells (in 
vitro) directly or indirectly requires further research.
4.1.2.3 Hyperactivation results in hyperproliferation of p21-/- effector/memory T cells after 
secondary stimulation
As activation precedes proliferation, we examined the proliferation rates of B6 and p21-/- 
effector/memory T cells after secondary stimulation.  Cell cycle profiles showed hyperproliferation 
of p21-deficient effector/memory T cells compared to their control counterparts.  Apoptosis was 
inhibited efficiently by zVAD in both cell types (Fig. 4.6A).  This finding was confirmed by increased 
[3H] thymidine incorporation in p21-/- CD4+ T cells compared to B6 CD4+ T cells after 48 h, with 
significant differences in proliferation rates whether or not the inhibitor zVAD was present (-zVAD: 
B6, 20701xcpm vs. p21-/-, 52734 cpm; p = 0.011; +zVAD: B6, 41758 cpm vs. p21-/-, 115767 cpm, 
px= 0.017) (Fig 4.6B).  Any interference of zVAD with the results can thus be excluded.  Finally, 
CFSE dilution assay showed that restimulated p21-deficient effector/memory T cells undergo more 
rounds of cell cycle division over time than controls (Fig. 4.6C).  To verify the ConA stimulation 
results, we used anti-CD3/CD28 antibodies to stimulate the cells in a TCR-specific manner.  Again, 
p21-/- CD4+ effector/memory T cells proliferated more in response to TCR challenge, as determined 
by [3H] thymidine incorporation (-zVAD: B6, 6642 vs. p21-/-, 10723 cpm, p = 0.001; +zVAD: B6, 
7868 vs. p21-/-, 13282 cpm, p = 0.012) (Fig. 4.6D) and CFSE dilution assay (Fig. 4.6E).  These data 
showed that lack of p21 leads to hyperactivation of memory-phenotype T cells and thus to their 
hyperproliferation.
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Fig. 4.6.  p21-deficient effector/memory T cells hyperproliferate after secondary TCR stimulation.  A. Cell cycle analysis 
of B6 and p21-/- CD4+ effector/memory T cells at 24 h post-secondary stimulation in the presence of zVAD (50 μM). 
Representative data are shown (n = 8).  B. [3H] thymidine uptake at 48 h after secondary stimulation with ConA, alone or 
with zVAD (50 μM).  Values show mean ± SD (n = 8; -zVAD: p = 0.011; +zVAD: p = 0.017).  C. CFSE dilution rate of gated PI-
negative cells after 24, 48 and 72 h of secondary stimulation with ConA in the presence of zVAD (50 μM).  Representative 
histograms are shown (n = 4).  D. Hyperproliferation of p21-/- effector/memory T cells measured by [3H] thymidine 
incorporation at 48 h after a second stimulation with anti-CD3/CD28 antibodies (+ 12.5 μM zVAD).  Values show mean 
± SD (n = 2; -zVAD: p = 0.001; +zVAD: p = 0.012).  E. Dilution rate of CFSE-labeled PI-negative WT and p21-/- effector/
memory T cells at 48 h post-restimulation with anti-CD3/CD28 antibodies (+ 12.5 μM zVAD).  Representative data are 
shown (n = 2).
4.1.2.4 Hyperproliferation of p21-deficient effector/memory T cells is CDK2-independent
After observing hyperactivation and hyperproliferation of effector/memory T cells in the 
absence of p21, we tested whether increased CDK2 activity might be the reason for this behavior, 
as p21 is a direct inhibitor of this kinase88.  In such a case, increased kinase activity would induce 
hyperproliferation, and continous proliferation could lead to hyperactivation of effector/memory 
T cells.  Kinase activity experiments supported our hypothesis and showed no notable changes 
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in CDK2 activity in the absence of p21, either at early (Fig. 4.7A) or at later times after secondary 
stimulation (Fig. 4.7B) in our culture conditions.
Figure 4.7.  Lack of p21 does not influence CDK2 activity in effector/memory T cells.  A,B. CDK2 activity levels in WT 
and p21-/- effector/memory T cells at short (A) and long times (B) after secondary ConA stimulation in the presence of 
zVAD (12.5 μM), as determined by kinase assays.  Histone H1 was used as substrate.  Western blot analysis of total CDK2 
and β-actin expression was used as loading control.  Representative experiments are shown (n = 2).  C. Kinase assay to 
determine CDK2 activity during a secondary stimulation in the presence of the CDK2 inhibitor CVT-313 (2.5 μM).  D,E.
[3H] thymidine uptake at 48 h after secondary (D) or primary stimulation (E) with ConA in untreated (DMSO) or CVT-313-
treated (1 μM or 2.5 μM) cells.  Values show mean ± SD (n = 2; D: p21-/- DMSO vs. CVT-313 1 μM, p = 0.022; p21-/- DMSO 
vs. CVT-313 2.5 μM, p = 0.0012; B6 DMSO vs. CVT-313 2.5 μM, p = 0.081; E: p21-/- DMSO vs. CVT-313 1 μM, p = 0.0148; 
p21-/- DMSO vs. CVT-313 2.5 μM, p = 0.0145; B6 DMSO vs. CVT-313 2.5 μM, p = 0.00001).
 To further show that p21 does not control CDK2 activity in CD4+ effector/memory T cells, we 
used the specific CDK2 inhibitor CVT-313124,125 during the repeated stimulation protocol and monitored 
T cell proliferation.  The difference in CDK2 activity observed at 4 and 24 h in normalxconditions 
(Fig. 4.7A) was minimized in the presence of CVT-313, confirming inhibitor function (Fig. 4.7C). 
During secondary TCR challenge, proliferation of both strains in the presence of CVT-313 was only 
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slightlyxreduced (Fig. 4.7D), which suggests that in fact p21 controls the cell cycle via pathways 
other than classical CDK2 inhibition in effector/memory T cells.  In contrast, proliferation of naïve 
Txcells was almost abolished in the presence of CVT313 (Fig. 4.7E), in accordance with our previous 
observation that p21 controlled CDK2 activity after first stimulation (Fig. 4.1B).  CDK2 activity thus 
appears to be irrelevant for proliferation after a secondary stimulation.
4.1.2.5 p21 is unrelated to TCR proximate events
As p21 appeared to be involved in T cell activation, we analyzed the effect of p21 on T cell 
activation pathways more closely.  Using the phorbol ester PMA (phorbol 12-myristate 13-acetate), 
which mimics the function of the second messenger diacylglycerol (DAG) and stimulates protein 
kinase C (PKCθ)133, we are able to bypass TCR proximate events and can activate intracellular molecules 
directly.  To test whether p21 has a role in early events after TCR activation or in downstream 
pathways, we restimulated B6 and p21-/- CD4+ T cells simultaneously with distinct stimulating agents, 
ConA and a combination of PMA and the calcium ionophore ionomycin. After ConA stimulation, 
we observed hyperphosphorylation of ERK1/2 in CD4+ T cells that lacked p21, confirming previous 
experiments (Fig. 4.8A).  We nonetheless detected a similar ERK1/2 phosphorylation pattern after 
stimulating cells with PMA/ionomycin (Fig. 4.8B).  This finding suggested that p21 does not have a 
TCR proximal role and is more likely to act on PCKθ or in downstream T cell activation pathways.
Figure 4.8.  p21 does not play a TCR proximal role.  A,B. B6 and p21-/- CD4+ T cells were restimulated in parallel in a TCR-
dependent manner with ConA (A) and in a TCR-independent manner with PMA/ionomycin (B); +50 μM zVAD was present 
in both conditions.  Western blot detection of ERK1/2 phosphorylation and p21 expression showed similar kinetics during 
secondary stimulation in both cases.  Total ERK1/2 and β-actin were used as loading controls.  A representative experiment 
is shown (n = 2).
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4.1.2.6 p21 is located in cytosol of memory-phenotype T cells
To determine whether p21 acts within the cytosolic or the nuclear compartment of memory 
T cells, we separated lysates from restimulated B6 and p21-/- CD4+ T cells into cytosolic and nuclear 
fractions prior to Western blot analysis.  p21 was detected mainly within the cytosol of B6 CD4+ 
effector/memory T cells, and ERK1/2 appeared to be hyperphosphorylated in the cytoplasm 
of p21-deficient CD4+ effector/memory T cells (Fig. 4.9A).  Within the nuclear fraction, p21 was 
hardly detectable in B6 CD4+ T cells and ERK1/2 was hyperphosphorylated in the absence of p21 
(Fig. 4.9B).
To confirm these results, we performed confocal microscopy and found p21 in the cytoplasm 
of B6 CD4+ effector/memory T cells (Fig. 4.9C); as predicted, p21 was not detectable in p21-/- CD4+ 
T cells.  In B6 CD4+ T cells, phospho-ERK1/2 concentrated around the nucleus, whereas phospho-
ERK1/2 was visible in both cytoplasm and nucleus of p21-deficient CD4+ T cells (Fig. 4.9C).  These 
observations indicate that p21 exerts its role within the cytosol, and that its absence leads to 
increased levels of phosphorylated ERK1/2 in nucleus and cytoplasm.
Figure 4.9.  Cytoplasmic localization of p21 and phosphorylated ERK1/2 in memory-like T cells after secondary 
stimulation.  A,B. Western blot analysis of cell fractions from ConA-restimulated B6 and p21-/- CD4+ T cells, showing 
cytoplasmic (A) and nuclear (B) localization of p21, phosphorylated ERK1/2 and total ERK1/2.  β-actin and histone 
H3 were used as loading controls, respectively.  A representative experiment is shown (n = 2).  C. Confocal analysis of 
phosphorylated ERK1/2 and p21 localization in cells at 24 h after secondary ConA stimulation.  Cells were antibody-stained 
to detect phospho-ERK1/2 (green) and p21 (red) and mounted with DAPI (blue)-containing mounting medium for confocal 
microscopy.  Representative results are shown (n = 2).
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4.1.2.7  Implication of p21 in the NFAT activation pathway
Another pivotal pathway in T cells leads to activation of the transcription factor NFAT, which 
together with AP-1 and NF-κB is essential for proinflammatory cytokine production134,135.  As NFAT 
activation is mediated by a rapid increase in free intracellular calcium (Ca2+) upon TCR stimulation, we 
tested whether the lack of p21 affected calcium release in effector/memory T cells.  TCR stimulation 
with anti-CD3/CD28 antibodies led to comparable Ca2+ influx levels in both B6 and p21-deficient 
CD4+ T cells (Fig. 4.10A).  We next analyzed direct NFAT activity.  EMSA showed higher NFAT activity 
in restimulated p21-/- effector/memory T cells after 24 h, which was maintained (Fig. 4.10B).  In 
comparison, NFAT activity in B6 effector/memory T cells decreased after 24 h post-secondary TCR 
challenge.
Consistent with previous findings (Fig. 8A,B), Ca2+ flux analysis indicated that p21 was not 
implicated in TCR proximal events and was thus not directly responsible for higher NFAT levels in 
p21-/- memory T cells.  A possible explanation for elevated NFAT activity in p21-deficient effector/
memory T cells is a feedback mechanism induced by other activation pathways that are dysregulated 
in the absence of p21.
Figure 4.10.  p21 is not involved in early Ca2+ responses or NFAT activation after TCR-mediated cell activation. 
A. Intracellular calcium responses of B6 and p21-/- effector/memory T cells to TCR-specific stimulation with anti-CD3/CD28 
antibodies (5 μg/ml and 1 μg/ml, respectively) after a 6-d IL-2 expansion phase.  For direct store depletion, T cells were 
stimulated with ionomycin (1 μg/μl).  Representative fluorescence traces from Fluo3-AM-loaded cells are shown (n = 2). 
B. Elevated NFAT activation levels in p21-/- effector/memory T cells after secondary ConA stimulation in the presence of 
zVAD (50 μM), as detected by EMSA.  A representative experiment is shown (n = 2).
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4.1.2.8 p21 controls ERK activation in effector/memory T cells
To show that increased ERK phosphorylation in p21-/- T cells constitutes a critical pathway for 
their hyperactivation and proliferative advantage, we inhibited ERK1/2 phosphorylation.  To study 
the direct effect of absence of ERK1/2 activation on p21-/- effector/memory T cell hyperproliferation, 
we treated both B6 and p21-/- CD4+ T cells with the MEK inhibitor U0126 during secondary ConA 
stimulation.  This molecule selectively interrupts MAPK cascade signal transduction and thus 
impedes ERK1/2 phosphorylation122.  In the presence of U0126, we observed a clear reduction 
in ERK1/2 phosphorylation, which confirmed inhibitor efficiency in our model (Fig. 4.11A).  We 
subsequently monitored division rates of CFSE-labeled B6 and p21-/- CD4+ T cells over time after 
secondary stimulation, and found reduced proliferation in both cell types in the presence of U0126 
(Fig. 4.11B).  Restimulated p21-/- memory T cells were more susceptible to the inhibitor, however, 
as their proliferation was reduced to a greater extent compared to B6 effector/memory T cells 
(Fig. 4.11B).  Significantly reduced proliferation of p21-deficient CD4+ T cells in the presence of U0126 
was also evident in [3H] thymidine incorporation assays, whereas the decrease in B6 CD4+ Txcell 
proliferation was not significant (p21-/-: -U0126, 102,546 vs. +U0126, 26893 cpm, p = 0.0002; B6: 
U0126, 18390 vs. +U0126, 7704 cpm, p = 0.177) (Fig. 4.11C).  These findings confirmed the result that 
hyperproliferation of effector/memory T cells lacking p21 is dependent on ERK phosphorylation. 
To analyze the effect of the inhibitor U0126 specifically on effector/memory T cells, we 
performed a BrdU incorporation assay in vitro.  Whereas the proliferation of B6 CD4+CD44highCD62Llow 
memory T cells was almost the same in the presence of the inhibitor, we observed a great reduction 
in p21-/- CD4+CD44highCD62Llow memory T cells (Fig. 4.11D).  These results indicate that autoreactive 
p21-deficient effector/memory T cells were more sensitive to inhibitor treatment and that p21 
controls proliferation of effector/memory T cells via ERK1/2 phosphorylation.
Finally, we examined the kinase activity of CDK2 in the presence of U0126 and detected 
similar CDK2 activity levels in B6 and p21-/- CD4+ T cells treated with DMSO or U0126 (Fig. 4.11E). 
These data indicate that hyperproliferation of p21-deficient effector/memory T cells is ERK-
dependent, and that p21 does not control the proliferation via the classical CDK2 pathway.
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Figure 4.11.  p21 controls proliferation of effector/memory T cells via ERK1/2 activation.  A. Western blot reflecting the 
reduction in ERK1/2 phosphorylation in B6 and p21-/- effector/memory T cells in the presence of U0126 (10 mM) after 
ConA secondary stimulation.  β-actin was used as a loading control.  A representative experiment is shown (n = 4).  B. CFSE 
dilution experiments in p21-/- and B6 memory T cells at 24, 48 and 72 h after secondary ConA stimulation in the presence of 
U0126 (10 mM) and zVAD (50 μM).  In all cases, representative data are shown (n = 2).  C. [3H] thymidine incorporation of 
U0126-treated (10 mM) restimulated B6 and p21-/- CD4+ effector/memory T cells at 48 h after secondary ConA stimulation. 
Values show mean ± SD (n = 5; B6, p = 0.177; p21-/-, p = 0.0002).  D. In vitro BrdU incorporation by CD4+CD44highCD62Llow 
B6 and p21-/- T cells restimulated with ConA for 24 h in the presence of zVAD (50 μM) and U0126 (10 mM) compared to 
DMSO-treated cells.  A representative experiment is shown (n = 2).  E. Kinase assay showing CDK2 activity in both B6 and 
p21-/- effector/memory T cells during secondary ConA stimulation in the presence of zVAD (50 μM) and U0126 (10 mM) or 
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DMSO.  Histone H1 was used as substrate.  Western blot analysis of total CDK2 and β-actin expression was performed as 
loading control.  A representative experiment is shown (n = 2).
Although ERK1/2 phosphorylation is one of the earliest events following TCR engagement, a 
second phase of ERK1/2 activation is thought to play an important role in mediating sustained T cell 
activation136.  To study whether the early ERK1/2 phosphorylation phase is sufficient to induce the 
hyperproliferation observed in p21-/- memory T cells or if later hyperactivation (between 14 h and 
24 h) is relevant for hyperproliferation, we added U0126 to the cell culture at different time points 
of secondary stimulation, and compared the results to DMSO-treated cells.  Western blot detection 
of phospho-ERK1/2 confirmed inhibitor efficiency in all conditions tested (Fig. 4.12A).
In terms of proliferation, [3H] thymidine incorporation showed a significant reduction in 
restimulated p21-deficient CD4+ T cells when U0126 was added at 6 h post-secondary stimulation 
(p21-/-, 102,546 vs. 31227 cpm, p = 0.0003).  We observed similar proliferation levels in B6 and p21-/- 
CD4+ T cells cultured with inhibitor from the start of stimulation (time 0) compared to cells treated 
with U0126 after 6 h.  In B6 CD4+ T cells, the reduction was not significant (B6, 18390 vs. 8871 cpm, 
p = 0.207) (Fig.12B).  Dilution assays that compared proliferation rates of CFSE-labeled B6 and p21-/- 
effector/memory T cells confirmed fewer cell divisions in p21-deficient CD4+ T cells, regardless of 
the time at which inhibitor was added to the culture (Fig. 4.12C).  We conclude that continuous 
ERK phosphorylation is necessary for hyperactivation and subsequent hyperproliferation of p21-
deficient memory T cells.
Figure 4.12.  p21 controls late ERK activation and proliferation of effector/memory T cells.  A. Western blot confirming 
reduced ERK1/2 phosporylation in the presence of the ERK1/2 inhibitor U0126 (10 mM) added at 0 h or 6 h of ConA 
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restimulation.  β-actin was used as loading control.  A representative experiment is shown (n = 5).  B. [3H] thymidine 
uptake at 48 h after the second TCR challenge in B6 and p21-/- effector/memory T cells, with U0126 (10 mM) added at 0 h 
or 6 h post-stimulation (p = 0.0003).  Values show mean ± SD (n = 5).  C. Dilution rate of CFSE-labeled PI-negative B6 (top 
panel) and p21-/- memory T cells (bottom panel) at 96 h after the second ConA stimulation and U0126 treatment at 0/6 h 
or DMSO control.  Representative data are shown (n = 3).
4.1.2.9 p21 regulates activation of NF-κB in memory-phenotype T cells
As we observed an increase in AP-1 activity and subsequent cytokine release in vitro (Fig. 
4.5C-E) as well as higher NFAT activity (Fig. 4.10B) in the absence of p21, we evaluated whether p21 
also influenced the activity of the transcription factor NF-κB, another important T cell activation 
marker crucial for cytokine production37.  We found hyperactivated NF-κB in p21-/- effector/memory 
T cells at 14 h after secondary stimulation, with maximum activation at 24 h (Fig. 4.13A).  We also 
tested whether this hyperactivation was detectable in earlier stages post-secondary TCR challenge, 
and observed elevated levels of active NF-κB at early times (30 min) after secondary stimulation (Fig. 
4.13B).  p21 thus has an essential role in early activation of effector/memory T cells, and controls 
both MAPK and NF-κB activation pathways.
As we found that p21 also regulates effector/memory T cell activation and proliferation via 
the NF-κB pathway, we used the NF-κB inhibitor BAY11-7082 to study its effect on p21-deficient T cell 
hyperproliferation.  BAY11-7082 selectively inhibits IKKα and subsequent IκBα phosphorylation, thus 
retaining NF-κB dimers in their inactive state123.  In the presence of BAY11-7082, NF-κB activity was 
greatly reduced, confirming similar inhibitor efficiency in B6 and p21-/- CD4+ T cells (Fig. 4.13C).  [3H] 
thymidine incorporation assays showed significantly reduced p21-deficient T cell proliferation levels 
in the presence of BAY11-7082 (13500 vs. 6549 cpm, p = 0.004), whereas B6 memory T cell proliferation 
diminished only moderately (7088 vs. 4284 cpm, p = 0.10) (Fig. 4.13D).  To examine whether early 
or late NF-κB activation was responsible for the p21-/- effector/memory T cell hyperproliferation 
observed previously (Fig. 4.6), we added BAY11-7082 at 6 h after secondary TCR challenge and compared 
the proliferation rates to cells treated at 0 h with DMSO or BAY11-7082.  At 6 h post-TCR stimulation, 
we found that proliferation was nearly abolished in both cell types (B6: -BAY11-7082, 14041  vs. 
+BAY11-7082, 1510 cpm, p = 0.055; p21
-/-: -BAY11-7082, 50757 vs. +BAY11-7082, 2216 cpm, p = 0.0005) (Fig. 
4.13E).  These data suggest that in addition to ERK1/2 phosphorylation, hyperproliferation of p21-
deficient effector/memory T cells depends on late hyperactivation of NF-κB.
To determine whether CDK2 activity influenced NF-κB activation, we performed secondary 
stimulation in the presence of the CDK2 inhibitor CVT-313.  EMSA showed elevated NF-κB activation 
levels in p21-/- effector/memory T cells after CVT-313 treatment compared to controls (Fig. 4.13F). 
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As NF-κB activity was unaffected by CDK2 inhibition, we propose that NFκB activation is independent 
of CDK2 in effector/memory T cells.
Figure 4.13.  Increased NF-κB activation in effector/memory T cells in the absence of p21.  A,B. NF-κB activation in 
p21-/- effector/memory T cells compared to B6 controls, as determined by EMSA at long (A) and short times (B) after 
secondary ConA stimulation in the presence of zVAD (50 μM).  Probe containing the NF-Y consensus sequence was used 
as a loading control.  Representative experiments are shown (n = 4).  C. EMSA showed reduced NF-κB activation after 
BAY11-7082 (10xμM) treatment of B6 and p21
-/- effector/memory T cells during secondary stimulation in the presence of 
zVAD (12.5 μM). Axrepresentative experiment is shown (n = 2).  D. Proliferation of B6 and p21-/- effector/memory T cells 
treated with BAY11-7082 (10 μM) at 48 h post-secondary ConA stimulation in the presence of zVAD (50 μM), determined by 
[3H] thymidine incorporation (B6: p = 0.10, p21-/-: p = 0.004).  Values show mean ± SD (n = 2).  E. Proliferation of B6 and 
p21-/- effector/memory T cells treated with BAY11-7082 (10 μM) at 0 h or 6 h in the presence of zVAD (12.5 μM), measured 
at 72 h post-secondary stimulation by [3H] thymidine incorporation.  Values show mean ± SD (n = 2; B6: p = 0.055, p21-/-: 
px= 0.0005).  F. Elevated NF-κB activity in p21-/- effector/memory T cells after treatment with CVT-313 (2.5μM), as detected 
by EMSA.  A representative experiment is shown (n = 2).
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4.2 p21-/- memory-like T cells hyperproliferate in response to specific antigens
As shown above, p21-deficient CD4+ memory T cells present a hyperactive state and 
proliferate intensely in response to repeated TCR stimulation with ConA in vitro.  To confirm our 
previous results, we next used a specific antigen (Ag) for repeated in vitro stimulation, to approximate 
a physiological stimulation model.  We purified CD4+ T cells that expressed a transgenic TCR (TCRtg) 
for chicken ovalbumin (OVA 323-339; OVA)119,120 from p21-deficient (p21-/- OT-II) and control mice 
(OT-II) and cultured them in vitro with dendritic cells (DC) previously loaded with OVA (1 μM) (see 
3.2.6).  These CD4+ T cells can be tracked by surface expression of the alpha chain (Vα2) in their 
transgenic TCR.
4.2.1 Similar proliferative response of naïve OT-II and p21-/- OT-II CD4+ T cells to primary 
stimulation with specific antigens in vitro
We first analyzed the in vitro response of purified naïve OT-II and p21-/- OT-II CD4+ T cells 
to TCR-specific stimulation with OVA peptide presented by DC in mixed cell cultures (Fig. 4.14A). 
[3H] thymidine incorporation was similar for both T cell types at 24 h after stimulation (naïve OT-II, 
1911 vs. p21-/- OT-II, 1774 cpm, p = 0.615) (Fig. 4.14B).  Comparison of cell cycle profiles of CD4+Vα2+ 
T cells at 24 h after primary stimulation showed no differences in proliferation or apoptosis induction 
(Fig. 4.14C).  CFSE dilution assay showed that T cells of both types undergo the same number of cell 
divisions in response to specific antigen stimulation (Fig. 4.14D).  Activation markers such as CD69 
were expressed at similar levels on the surface of naïve OT-II and p21-/- OT-II CD4+ T cells (Fig. 4.14E), 
confirming comparable activation states in both cell types after primary TCR challenge.
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Figure 4.14.  Naïve OT-II and p21-/- OT-II CD4+ T cells show similar proliferation rates and activation states during first 
stimulation with OVA-presenting DC.  A. Primary stimulation in vitro of purified naïve OT-II and p21-/- OT-II CD4+ T cells with 
DC presenting OVA (1 μM) in the presence of hrIL-2.  Cells were co-cultured at 1 x 106/ml CD4+ and 1 x 105/ml DC (10:1) 
final concentration.  B. [3H] thymidine incorporation in naïve OT-II and p21-/- OT-II T cells at 24 h post-primary TCR challenge 
with OVA presented by DC.  Values show mean ± SD (n = 2; p = 0.615).  C. Cell cycle profiles of naïve OT-II and p21-/- OT-II 
(CD4+ Vα2+) T cells at 24 h after first stimulation.  Fixed cells were stained with DAPI (2 μg/ml) for DNAxquantification. 
Representative histograms are shown (n = 4).  D. CFSE dilution of gated live (PI-) CD4+ Vα2+ cells of naïve OT-II and p21-/- 
OT-II T cells at 72 h after first stimulation.  Representative histograms are shown (n = 2).  E. Surface expression of the 
CD69 activation marker on naïve OT-II and p21-/- OT-II CD4+ Vα2+ T cells stimulated for 24 h with OVA-presenting DC, as 
determined by flow cytometry.  Representative histograms are shown (n = 2).
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4.2.2 p21-deficient OT-II CD4+ T cells show a proliferative advantage after a second stimulation 
with OVA-presenting DC in vitro
Auto-reactive T cells that escape thymic selection migrate to peripheral tissues, where they 
are activated repeatedly by encountering their cognate auto-antigen.  To mimic this situation, we 
challenged OT-II and p21-/- OT-II CD4+ T cells for a second time in vitro with OVA-presenting DC in the 
presence of zVAD to avoid AICD (Fig. 4.15A).
Repeated stimulation with the TCR-specific OVA peptide presented by DC led to 
hyperproliferation of p21-/- OT-II CD4+ effector/memory T cells in comparison to control OT-II CD4+ 
memory T cells, as seen in cell cycle analysis (Fig. 4.15B).  A [3H] thymidine incorporation assay 
confirmed significantly higher proliferation rates of p21-deficient OT-II effector/memory T cells at 
48 h after secondary TCR challenge (OT-II, 39491 vs. p21-/- OT-II, 69579 cpm; p = 0.025) (Fig. 4.15C). 
In addition, an elevated number of cell divisions was observed for p21-/- OTII CD4+ effector/memory 
T cells in CFSE dilution assays compared to control counterparts (Fig. 4.15D).  In accordance with 
the apparent hyperproliferation of p21-deficient OT-II T cells, higher surface expression of CD69 was 
detected in these cells (Fig. 4.15E), confirming the hyperactive state of p21-/- OT-II CD4+ effector/
memory T cells after secondary TCR challenge. As a consequence of the elevated proliferation 
rate, we observed an accumulation of p21-deficient CD4+Vα2+ effector/memory T cells during 
restimulation (Fig. 4.15F).
By applying this in vitro model and stimulating CD4+ T cells in a more physiological manner 
for one or two consecutive times with OVA-loaded DC, we observed results similar to those obtained 
with ConA.  This antigen-specific stimulation model confirmed the hypothesis that p21 is involved in 
the cell cycle regulation of effector/memory, but not naïve CD4+ T cells.
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Figure 4.15.  Hyperproliferation of p21-/- OT-II CD4+ effector/memory T cells in response to antigen (OVA)-specific 
stimulation.  A. Secondary stimulation of OT-II and p21-/- OT-II CD4+ effector/memory T cells in vitro in the presence of DC 
presenting OVA (1 μM).  Cells were co-cultured at 1 x 106/ml CD4+ and 1 x 105/ml DC (10:1) final concentration.  B. Cell 
cycle analysis of CD4+ Vα2+ T cells at 48 h post-secondary stimulation (+12.5 μM zVAD).  Fixed cells were stained with DAPI 
(2 μg/ml) to quantify DNA.  Representative histograms are shown (n = 3).  C. Hyperproliferation of p21-/- OT-II effector/
memory T cells measured by [3H] thymidine incorporation at 48 h after the second stimulation by OVA-presenting DC 
(+ 12.5 μM zVAD).  Values show mean ± SD (n = 3; p = 0.025).  D. CFSE dilution rate of gated PI-negative CD4+ Vα2+ cells at 
72 h after secondary stimulation with OVA-presenting DC in the presence of zVAD (12.5 μM).  Representative histograms 
are shown (n = 3).  E. CD69 surface expression as determined by flow cytometry.  Representative histograms are shown 
(n = 2).  F. CD44/CD62L double staining to compare effector/memory T cell populations at 0 h and 72 h after secondary 
stimulation as determined by flow cytometry (n = 2).
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4.2.3 Hyperproliferation of p21-/- OT-II CD4+ T cells after secondary stimulation with specific 
antigens in vitro is mediated by NF-κB, not CDK2
After in vitro restimulation of B6 and p21-/- CD4+ T cells with ConA, we found that p21-
deficient effector/memory T cells were hyperactivated; as a result, we detected higher proliferation 
rates in these cells (Fig. 4.6).  We also observed that p21 did not control T cell proliferation via 
its typical effector kinase CDK2 (Fig. 4.7), but more likely via the NF-κB activation pathway (Fig. 
4.13).  To confirm these results in physiological conditions, we analyzed CDK2 kinase activity in 
OT-II and p21-/- OT-II CD4+ T cells after secondary stimulation with OVA-loaded DC, and found no 
differences in kinase activity between T cells of both types (Fig. 4.16A).  We nonetheless observed 
higher NF-κB activity in p21-/- OT2 effector/memory T cells (Fig. 4.16B), as also seen in p21-/- memory 
T cellsxstimulated with ConA (Fig. 4.13A,B).
Figure 4.16.  Hyperproliferation of p21-/- OT-II effector/memory T cells is NF-κB-dependent and independent of CDK2. A. 
CDK2 activity levels in OT-II and p21-/- OT-II effector/memory T cells during secondary stimulation with DC-presented OVA 
peptide in the presence of zVAD (12.5 μM), as determined by kinase assay.  Histone H1 was used as substrate.  Western 
blot analysis of total CDK2 and β-actin expression served as loading control.  A representative experiment is shown . 
(n = 2).  B. EMSA showing NF-κB activation in OT-II and p21-/- OT-II effector/memory T cells after secondary stimulation.  A 
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representative experiment is shown (n = 2).  C. Cell cycle analysis of PI- CD4+ Vα2+ T cells at 48 h after secondary stimulation 
in the presence of CVT-313 (2.5 μM) or BAY11-7082 (10 μM) (+ 12.5 μM zVAD).  Fixed cells were stained with DAPI (2 μg/ml) 
to quantify DNA.  Representative data are shown (n = 2).  D. Proliferation of OT-II and p21-/- OT-II effector/memory T cells 
in the presence of BAY11-7082 (10 μM) or CVT-313 (2.5 μM), measured by [
3H] thymidine uptake at 48 h after secondary 
stimulation (p21-/- OT-II: CVT-313, p = 0.0675; BAY11-7082, p = 0.0001).  Values show mean ± SD (n = 2).
For further confirmation, T cells of both types were restimulated in the presence of the 
inhibitors CVT-313 (CDK2) and BAY11-7082 (NF-κB) to study their effect on hyperproliferation of p21-
deficient OT-II T cells.  Cell cycle analysis showed only a moderate decrease in effector/memory T cell 
proliferation in the presence of CVT-313; in contrast, treatment with BAY11-7082 completely abolished 
T cell proliferation in both OT-II and p21-/- OT-II effector/memory T cells.  In both cases, apoptosis 
induction was unaffected (Fig. 4.16C).  [3H] thymidine incorporation assays showed that CVT-313 did 
not affect T cell proliferation rates (p21-/- OT-II, 19695 vs. 16065 cpm; p = 0.0675), whereas BAY11-7082 
completely inhibited proliferation in both OT-II and p21-/- OT-II CD4+ T cells (p21-/- OT-II, 19695 vs. 
59 cpm; p = 0.0001) (Fig. 4.16D).  These findings suggest that p21 controls effector/memory T cell 
proliferation via NF-κB and not via CDK2.
4.2.4  In vivo TCR-specific stimulation of naïve CD4+ T cells leads to hyperreactivity of p21-/- TCRtg 
T cells
To study the role of p21 in cell cycle control of effector/memory T cells in a more physiological 
context, we mimicked conditions of an immune response to allow us to monitor CD4+ T cell behavior 
in vivo.  We adoptively transferred TCR-transgenic naïve CD4+ T cells from OT-II or p21-/- OT-II mice to 
recipient mice of the same haplotype (C57BL/6).  The T cell population injected represents ~1% of 
all cells in secondary lymphoid organs, and can be detected and followed by the expression of the 
transgenic TCR (Vα2)137,138.
For these experiments, we purified TCRtg CD4+ from spleens of OT-II or p21-/- OT-II mice and 
labeled them with CFSE prior to injection into recipient mice (1 x 106 CD4+ T cells/mouse).  After 
24 h, we challenged with OVA-loaded DC (1 x 106 DC/mouse); three days later, mice were sacrificed 
and cells of secondary lymphoid organs were analyzed (Fig. 4.17A)129.
We examined the proliferative response of CD4+Vα2+ T cells to specific stimulation with 
OVA peptide in vivo by analyzing dilution of the CFSE proliferation marker in these cells.  Both OT-II 
and p21-/- OT-II T cells proliferated considerably (OT-II, blue curve; p21-/- OT-II, purple) compared to 
initial CFSE loading (solid black), but were still distinguishable from the CFSE-negative peak, which 
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represented endogenous CD4+ T cells (solid grey) (Fig. 4.17B).  No differences were observed when 
we compared the proliferation rates of OT-II and p21-/- OT-II T cells in spleen and lymph nodes.  Cell 
cycle analysis at 3 d post-stimulation confirmed similar proliferation and apoptosis levels in OT-II and 
p21-/- OT-II T cells in spleens and lymph nodes (Fig. 4.17C).
Figure 4.17.  In vivo TCR-specific stimulation does not alter naïve CD4+ T cell activation, but leads to hyperreactivity 
of p21-/- TCRtg effector/memory T cells ex vivo.  A. Purified CD4+ splenocytes from OT-II or p21-/- OT-II mice were CFSE-
labeled and adoptively transferred to B6 recipients.  After 24 h, the cells were challenged specifically by injection of DC 
presenting OVA peptide.  After 3 days, mice were sacrificed and the CD4+ T cell response was evaluated.  CD4+ splenocytes 
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received an additional OVA challenge ex vivo as indicated.  B. CFSE dilution of OT-II (blue) and p21-/- OT-II (purple) (CD4+ 
Vα2+) T cells 72 h after TCR-specific stimulation with DC in vivo.  Endogenous T cells (Vα2-; solid grey) and initial CFSE 
loading (CD4+ Vα2+; solid black) controls are shown.  A representative experiment is shown (n = 2).  C. Cell cycle analysis 
of CD4+ Vα2+ T cells in spleen and lymph nodes after primary stimulation in vivo.  Fixed cells were stained with DAPI 
(2μg/ml) for DNA quantification. Representative histograms are shown (n = 2).  D. Ex vivo restimulation of OT-II and p21-/- 
OT-II T cells with total splenocytes in the presence of soluble OVA peptide (1 μM) as determined by cell cycle analysis. 
Fixed  cells were DAPI-stained for DNA quantification.  Representative histograms are shown (n = 2).  E,F. [3H] thymidine 
incorporation in OT-II and p21-/- OT-II T cells after ex vivo restimulation with total splenocytes and soluble OVA peptide 
(1 μM/5 μM; 72 h) (E) or OVA-presenting DC (48 h; 10:1 CD4+:DC ratio) (F).  Values show mean ± SD (n = 2; 1 μM OVA, 
px=x0.0007; 5 μM OVA, p = 0.0004; CD4+:DC 10:1: p = 0.025).
Following primary stimulation in vivo, we observed no proliferation differences between 
OT-II and p21-/- OT-II T cells; we thus stimulated the cells for a second time ex vivo to confirm the 
importance of p21 in regulating proliferation in effector/memory T cells.  We restimulated total 
splenocytes in vitro with soluble OVA peptide; in this way, the spleen APC specifically stimulate 
the CD4+Vα2+ T cells.  Cell cycle analysis showed high proliferation levels for p21-/- OT-II T cells in 
comparison to OT-II T cells at 48 h after secondary stimulation ex vivo, while apoptosis levels remained 
similar (Fig. 4.17D).  [3H] thymidine incorporation confirmed significantly higher proliferation 
levels of p21-/- OT-II T cells, independently of the OVA peptide dose used for restimulation (1 μM 
OVA: OT-II, 3240 vs. p21-/- OT-II, 7508 cpm, p = 0.0007;   5 μM OVA: OT-II, 5498 vs. p21-/- OT-II, 
12634 cpm,.p = 0.0004) (Fig. 4.17E).  To exclude the possible influence of endogenous recipient 
mouse splenocytes on the outcome of the [3H] thymidine incorporation assay, we purified CD4+ T 
cells from spleens harvested 3 days after in vivo stimulation, and used OVA-loaded DC for ex vivo 
restimulation (10:1 CD4+:DC ratio).  We again observed p21-/- OT-II T cell hyperproliferation after 
secondary stimulation (OT-II, 39491 vs. p21/ OT-II, 69579 cpm, p = 0.025) (Fig. 4.17F).
4.2.5 p21-deficient TCRtg CD4+ T cells hyperproliferate in response to repeated stimulation with 
specific antigens of low and high affinity
The next objective was to study the regulatory effect of p21 on T cell responses to self-
antigens in physiological conditions, by stimulating the cells with a specific antigen.  We therefore 
used T cells that present a transgenic T cell receptor (TCRtg) for pigeon cytochrome C (PCC)126,127. 
Purified control (pcc.TCRtg) and p21-deficient (pcc.TCRtg-p21-/-) CD4+ T cells were cultured with 
irradiated APC of the same haplotype (see 3.2.5).  These T cells can be identified by expression of 
transgenic alpha (Vα11) and beta (Vβ3) TCR chains137,138.
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This mixed cell culture model allowed us to stimulate the CD4+ T cells with antigens that 
have high (PCC) or low affinity (A96I; PCC with an A>I subsitution at residue 96) for the transgenic 
TCR, to test whether loss of p21 expression in memory T cells affected the TCR-mediated activation 
threshold.  In response to auto-antigens with low affinity for the TCR139, T lymphocytes progressively 
lose tolerance to the antigen, leading finally to development of autoimmune diseases.  Greater 
susceptibility of p21-/- CD4+ T cells to stimulation by peptides with low TCR affinity would thus 
provide insight into the role of p21 in the CD4+ T cell response to auto-antigens, maintenance of 
tolerance, and the induction of autoimmune disorders.
4.2.5.1 pcc.TCRtg-p21-/- CD4+ T cells hyperproliferate in response to a secondary TCR challenge 
with high affinity antigens
To ensure appropriate activation of purified naïve pcc.TCRtg and pcc.TCRtg-p21-/- CD4+ 
T cells, for the first stimulation we used irradiated APC presenting an antigen with high affinity (PCC) 
for the transgenic TCR (Fig. 4.18A).  The A96I antigen with low affinity for the TCRtg is too weak to 
generate significant T cell responses and was not considered for naïve T cell stimulation (data not 
shown). After primary stimulation, [3H] thymidine incorporation showed no significant differences 
between naïve pcc.TCRtg and pcc.TCRtg-p21-/- T cells (pcc.TCRtg, 2036 vs. pcc.TCRtg-p21-/-, 2151xcpm, 
p = 0.7) (Fig. 4.18B).  Cell cycle profiles showed similar proliferation rates in naïve pcc-TCRtg and 
pcc.TCRtg-p21-/- CD4+ T cells; apoptosis levels were also similar and included dying irradiated APC in 
theiculture (Fig. 4.18C).  The proliferative response to primary stimulation with TCR-specific antigens 
in vitro is thus comparable in pcc.TCRtg and pcc.TCRtg-p21-/- naïve CD4+ T cells.
To study the role of p21 in the determination of the TCR activation threshold of effector/
memory T cells, we applied the repeated stimulation protocol to pcc.TCRtg and pcc.TCRtg-p21-/- 
CD4+ T cells.  T cells were expanded for 6 days in hrIL-2 and then restimulated with freshly isolated 
and irradiated APC.  For secondary stimulation, we used antigens with different affinities for the 
TCRtg (Fig. 4.18A) (see 3.2.5).
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Figure 4.18.  Hyperproliferation of pcc.TCRtg-p21-/- effector/memory T cells after a secondary TCR challenge in vitro 
with a high affinity antigen.  A. Naïve pcc.TCRtg and pcc.TCRtg-p21-/- CD4+ T cells were stimulated in vitro with irradiated 
APC (B10BR, 30 Gy) and PCC (3 μM) in the presence of hrIL-2 (20 ng/ml).  CD4+ T cells and APC were plated at a 1:3 ratio. 
After 6 days expansion with hrIL-2, CD4+ T cells were restimulated with freshly isolated and irradiated APC (CD4+:APC 
ratio 1:3) and an antigen with high TCR affinity (PCC) in the presence of zVAD (12.5 μM).  B. [3H] thymidine incorporation 
at 24 h after primary stimulation with PCC.  Values show mean ± SD, (n = 2, p = 0.7).  C. Cell cycle analysis of pcc.TCRtg 
and pcc.TCRtg-p21-/- CD4+Vb3+ T cells at 24 h after primary stimulation with PCC (3 μM) in mixed cell cultures (2 μg/ml 
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DAPI).  A representative experiment is shown (n = 2).  D. Cell cycle analysis (2 μg/ml DAPI) of pcc.TCRtg and pcc.TCRtg-
p21-/- CD4+Vb3+ T cells at 24 h after restimulation with PCC alone or with zVAD (12.5 μM).  A representative experiment is 
shown (n = 2).  E. [3H] thymidine incorporation in pcc.TCRtg and pcc.TCRtg-p21-/- T cells at 48 h after secondary stimulation 
with PCC.  Values show mean ± SD (n = 2; -zVAD: 0.1 μM, p = 0.0009, 1 μM, p = 0.0003; +zVAD: 0.1 μM, p = 0.00003, 1 μM, 
p = 0.071).
Whereas pcc.TCRtg and pcc.TCRtg-p21-/- CD4+ T cells showed a similar proliferative response 
to high affinity antigens (PCC) during primary stimulation, pcc.TCRtg-p21-/- effector/memory T cells 
hyperproliferated after secondary simulation with PCC, as observed by cell cycle analysis (Fig. 4.18D). 
In addition, restimulation with high affinity antigen induced high levels of apoptosis (Fig. 4.18D, left). 
This phenomenon, known as AICD, was slightly reduced in the presence of the apoptosis inhibitor 
zVAD at the usual concentration (12.5 μM) (Fig. 4.18D, right).  The [3H] thymidine incorporation 
assay confirmed p21-deficient pcc.TCRtg effector/memory T cell hyperproliferation in response to 
PCC (Fig. 4.18E).  Low [3H] thymidine incorporation in the absence of zVAD can be explained by 
the increased apoptosis levels observed in cell cycle profiles (0.1 μM PCC, p = 0.0009; 1 μM PCC, 
p = 0.0003) where, in the presence of zVAD, pcc.TCRtg-p21-/- CD4+ T cells clearly hyperproliferated 
compared to their pcc.TCRtg counterparts (0.1 μM PCC, p = 0.00003; 1 μM PCC, p = 0.071) (Fig. 
4.18E).  Low PCC doses (0.1 μM) induced higher proliferation levels than high PCC doses (1 μM) in 
pcc.TCRtg CD4+ T cells.  This finding was more evident in pcc.TCRtg-p21-/- CD4+ T cells (Fig. 4.18D,E) 
and indicated distinct activation thresholds in p21-deficient T cells.  These data suggested that 
second stimulation using an antigen with high affinity for the transgenic TCR leads to p21-deficient 
TCRtg T cell hyperproliferation, which confirmed our previous results after restimulation with ConA 
and anti-CD3/CD28 antibodies in vitro (Fig. 4.6).
4.2.5.2 TCRtg-p21-/- CD4+ T cells hyperproliferate in response to a second stimulation with weak 
affinity antigen
Self-reactive T cells that escape peripheral tolerance mechanisms (see 1.2) usually have low 
affinity for auto-antigens and play a central role in the pathogenesis of autoimmune diseases139. 
To study the role of p21 in the maintenance of tolerance and induction of autoimmunity, a specific 
antigen with low affinity for the TCRtg (A96I) was used for secondary stimulation of TCRtg CD4+ cells 
in vitro.
After restimulation of pcc.TCRtg and pcc.TCRtg-p21-/- effector/memory T cells with A96I, no 
AICD was induced (Fig. 4.19A, left) and apoptosis levels were hardly altered in the presence of zVAD, 
as observed in cell cycle profiles (Fig. 4.19A, right).  In addition, pcc.TCRtg-p21-/- effector/memory 
76
4.  RESULTS
T cells clearly hyperproliferated in response to A96I compared to pcc.TCRtg CD4+ Vβ3+ T cells (Fig. 
4.19A); the proliferation difference between both cell types was even greater than after secondary 
PCC stimulation (Fig. 4.18D).  The elevated proliferative capacity of pcc.TCRtg-p21-/- effector/memory 
T cells was verified by [3H] thymidine incorporation at 48 h after secondary stimulation with A96I 
(1 μM and 10 μM) alone or in the presence of zVAD (12.5 μM) (-zVAD: 1 μM A96I, p = 0.006, 10 μM 
A96I, p = 0.0003; +zVAD: 1 μM A96I, p = 0.001, 10 μM A96I, p = 0.03) (Fig. 4.19B).  p21-deficient 
pcc.TCRtg T cells proliferated up to 2.5 times more compared to pcc.TCRtg T cells in response to high 
doses of A96I (10 μM).  In accordance with previous results, a CFSE dilution assay confirmed the 
finding that pcc.TCRtg-p21-/- effector/memory T cells undergo more rounds of cell division than their 
pcc.TCRtg counterparts (Fig. 4.19C).  The hyperproliferation of p21-deficient pcc.TCRtg CD4+ T cells 
in response to a low affinity antigen points to a lower TCR activation threshold in these cells. pcc.
TCRtg-p21-/- effector/memory T cells might thus be more susceptible to activation by auto-antigens, 
which could lead to loss of tolerance.
Figure 4.19.  The low affinity antigen A96I induces hyperproliferation of TCRtg-p21-/- memory-phenotype CD4+ T cells. 
A. Cell cycle analysis of pcc.TCRtg and pcc.TCRtg-p21-/- effector/memory T cells at 24 h after secondary stimulation with 
A96I (1 μM and 10 μM) alone (left) or with zVAD (12.5 μM; right) (2 μg/ml DAPI).  A representative experiment is shown 
(n = 2).  B. [3H] thymidine incorporation in pcc.TCRtg and pcc.TCRtg-p21-/- effector/memory T cells at 48 h after secondary 
TCR challenge with A96I (1 μM and 10 μM) alone or with zVAD (12.5 μM).  Values show mean ± SD (-zVAD: 1 μM A96I, 
p = 0.006, 10 μM A96I, p = 0.0003; +zVAD: 1 μM A96I, p = 0.001, 10 μM A96I, p = 0.03; n = 2).  C. CFSE dilution assay of pcc.
TCRtg and pcc.TCRtg-p21-/- effector/memory T cells at 96 h after secondary stimulation with 10 μM A96I (+ 12.5 μM zVAD). 
A representative experiment is shown (n = 2).
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4.3 The role of p21 in the development of autoimmune disease in B6/lpr mice
Thus far, in addition to its known function as a cell cycle inhibitor, we identified p21 as 
a negative regulator of memory T cell activation and proliferation.  p21 therefore appears to be 
important for establishment of T cell tolerance and for autoimmune suppression, as it prevents 
immune responses to antigens with low TCR affinity, which mimic auto-antigens.
To study the role of p21 in an in vivo model of autoimmunity, we used B6/lpr mice. 
These mice have Fas deficiency, which leads to defective apoptosis signaling and development 
of autoimmune disorders, characterized by lymphadenopathy and splenomegaly (see 1.5.2).  In 
addition, elevated levels of anti-DNA antibodies in serum, immune complex formation in tissues and 
mild glomerulonephritis are detected.  These alterations could lead to kidney failure, but in general 
a mild, non-lethal course of disease is observed in B6/lpr mice56.  As both Fas and p21 are essential to 
restrain T cell activation and proliferation, we generated B6/lpr-p21-deficient mice on the C75BL/6 
background (B6/lpr-p21-/-) to study T cell responses and the development of autoimmunity in mice 
lacking Fas and p21.
4.3.1  Lack of p21 exacerbates the autoimmune manifestations in B6/lpr mice
A common characteristic in B6/lpr pathology is the presence of anti-DNA antibodies in 
serum of Fas-deficient mice (see 1.5.2).  As a direct result of the immunological hyperactivation 
in the absence of p21, significantly higher levels of anti-DNA antibodies of all IgG isotypes were 
detected in 8-month-old B6/lpr-p21-/- mice (data not shown).  High levels of IgG auto-antibodies 
have an important role in the development of glomerulonephritis42,55,57, a common manifestation 
in pathology of B6/lpr mice. Autoimmune nephritis is caused by the accumulation of immune 
complexes composed of DNA and anti-DNA-antibodies, and subsequent activation and infiltration 
of inflammatory cells.
We analyzed kidney paraffin sections of 6-month-old B6, p21-/-, B6/lpr and B6/lpr-p21-/- 
mice and observed glomerular inflammation and an increase in mesangial matrix in B6/lpr mice 
(grade III lupus nephritis according to Weening and co-workers132), whereas no alteration in the 
glomerulus was found in B6 controls (Fig. 4.20A, left).  The lack of p21 caused a serious aggravation 
of the pathologic manifestation in p21-/- (grade II) and B6/lpr-p21-/- mice (grade IV) compared to B6 
and B6/lpr mice, respectively (Fig. 4.20A, right).  Lack of both Fas and p21 had an additional effect, 
with more severe disease pathology in B6/lpr-p21-/- mice.
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The maintained inflammation state leads to structural degradation of the glomerulus and 
thus to protein precipitation in the urine of Fas-deficient mice with lupus-like disease.  We confirmed 
increased protein levels in the urine of B6, p21-/-, B6/lpr and B6/lpr-p21-/- mice (9 months and older) 
(Fig. 4.20B) corresponding to the lupus nephritis grades previously described (Fig. 4.20A).  The 
absence of p21 aggravated autoimmune manifestations in B6 and B6/lpr mice, resulting in severe 
glomerulonephritis in B6/lpr-p21-/- mice.
Figure 4.20.  Lack of p21 aggravates autoimmune glomerulonephritis in B6 and B6/lpr mice.  A. Light micrographs of 
representative kidney sections from 6-month-old female B6, p21-/-, B6/lpr and B6/lpr-p21-/- mice (n = 4 mice/group). 
Lupus nephritis grades according to the scale defined by Weening et al.132 are indicated.  B. Detection of protein levels in 
urine of B6, p21-/-, B6/lpr and B6/lpr-p21-/- mice (n ≥27 mice/group; 9 months and older).
To determine the effect of p21 deficiency on autoimmune manifestations at the cellular 
level, we analyzed several T cell populations from B6/lpr and B6/lpr-p21-/- mice and their implication 
in disease development in vivo.  An important characteristic of the B6/lpr phenotype is accumulation 
of TCRβ+CD4-CD8- (DN), CD4+CD44highCD62Lhigh (effector phenotpye) and CD4+CD44highCD62Llow 
(memory phenotype) T cells in secondary lymphoid organs.  The excessive proliferation of DN T cells 
is thought to cause lymhadenopathy over time73,77. In vivo analysis of DN populations, however, 
did not show marked differences in the percentage of TCRβ+CD4-CD8- T cells between B6/lpr and 
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B6/lpr-p21-/- mice (Fig. 4.21A).  The proliferative response of DN cells in vivo was also comparable, 
as determined by a BrdU incorporation assay (Fig. 4.21B).  The lack of p21 thus did not alter DN 
T cells in B6/lpr mice.
Figure 4.21.  DN T cell accumulation and proliferation is similar in B6/lpr and B6/lpr-p21-/- mice.  A. CD4 and CD8 double 
staining, gated on TCRβ+ T cells isolated from lymph nodes of 8-month-old B6/lpr and B6/lpr-p21-/- mice.  Representative 
data are shown (n = 3 mice/strain).  B. Similar proliferative response of B6/lpr and B6/lpr-p21-/- DN T cells in vivo (1 month 
old).  BrdU was administered in drinking water for 9 days.  A representative experiment is shown (n = 2).
4.3.2 Hyperactivation of CD44highCD62Llow memory T cells in B6/lpr-p21-/- mice
We next examined whether CD44highCD62Lhigh and CD44highCD62Llow memory T cell populations 
were influenced by the lack of p21 in B6/lpr mice.  At one month of age, B6/lpr-p21-/- mice already 
presented indications of CD44highCD62Llow memory T cell accumulation (Fig. 4.22A, left). When 
mice reached the age of 8 months, the percentage of CD44highCD62Llow cells was clearly increased 
in B6/lpr-p21-/- mice, whereas the CD44highCD62Lhigh population was reduced (Fig. 4.22A, right).  We 
found both memory T cell populations, and CD4+ T cells in general, to be hyperactivated in B6/lpr-
p21-/- mice compared to B6/lpr mice,  as indicated by staining for cell surface activation markers 
CD25 (Fig. 4.22B) and CD69 (data not shown).  These findings suggest a regulatory role for p21 in 
activation of potentially auto-reactive memory T cells.
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Figure 4.22.  Hyperactivation and increased representation of CD44highCD62Llow memory T cells in B6/lpr-p21-/- mice. 
A. CD44-CD62L double staining gated on CD4+ T cells isolated from lymph nodes of 1- or 8-month-old B6/lpr and 
B6/lpr-p21-/- mice.  Representative data are shown (n = 3 mice/strain).  B. Surface expression of CD25 on CD4+ (top panel), 
CD4+CD44highCD62Lhigh (middle) and CD4+CD44highCD62Llow (bottom) T cells from 8-month-old B6/lpr and B6/lprp21-/- mice, 
as determined by flow cytometry.  Representative histograms are shown (n = 3 mice/strain).
4.3.3 B6/lpr-p21-/- memory-phenotype T cells present a hyperactive state in vitro
To analyze the influence of p21 in B6/lpr T cell responses in vitro, we applied the repeated 
stimulation system to B6/lpr and B6/lpr-p21-/- T cells (Fig. 4.4A).  Freshly isolated naïve CD4+ T cells 
from 2-month-old mice were stimulated twice with ConA, and factors of the most important T cell 
activation pathways were analyzed in response to a secondary antigen encounter.
We found that B6/lpr-p21-/- effector/memory T cells were hyperactivated compared to 
B6/lpr memory T cells, reflected by increased ERK1/2 phosphorylation levels after restimulation 
(Fig. 4.23A).  We also observed elevated NF-κB activation levels in B6/lpr-p21-/- memory T cells 
during a secondary ConA stimulation (Fig. 4.23B).  The activity of other key transcription factors 
such as NFAT was unaltered in B6/lpr-p21-/- T cells (Fig. 4.23C).  To confirm B6/lpr and B6/lpr-p21-/- 
memory T cell hyperactivation, we analyzed pro-inflammatory cytokine production in response toia 
secondary TCR challenge in vitro, and detected elevated IFNγ, IL-17 and IL-2 production in B6/lpr-
p21-/- memory T cells (Fig. 4.23D).  These findings concur with our data for B6 and p21-/- memory 
Txcells, and confirm the importance of p21 as a negative regulator of T cell activation via ERK1/2 
and NF-κB.
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Figure 4.23.  p21 controls T cell activation pathways in B6/lpr-p21-/- effector/memory T cells in vitro.  A. Western blot 
analysis of ERK1/2 phosphorylation kinetics in B6/lpr and B6/lpr-p21-/- effector/memory T cells at indicated times after 
secondary ConA stimulation (1.5 μg/ml).  A representative experiment is shown (n = 2).  B. NF-κB activation levels in 
B6/lpr-p21-/- effector/memory T cells after secondary stimulation as detected by EMSA.  A representative experiment is 
shown (n = 2).  C. NFAT activation levels in B6/lpr-p21-/- effector/memory T cells after secondary stimulation, as detected 
by EMSA.  A representative experiment is shown (n = 2).  D. Percentage of CD44highCD62Lhigh T cells positive for intracellular 
staining of IFNγ (left), IL-17 (middle) and IL-2 (right) at 4 h after secondary stimulation with PMA (40 ng/ml) and ionomycin 
(1 μg/ml) at 1 x 106 cells/ml (n = 3; p values are indicated: ** = < 0.01; *** = < 0.001).
 4.3.4 Lack of p21 leads to hyperproliferation of B6/lpr CD4+ memory-like T cells in vitro
To determine whether the T cell hyperactivation in the absence of p21 had any effect on other 
B6/lpr CD4+ T cell responses, we monitored proliferation after primary and secondary stimulation 
in vitro.  At 24 h after the first TCR challenge, cell cycle analysis showed comparable proliferation 
and apoptosis levels (Fig. 4.24A).  No significant proliferative differences between naïve B6/lpr and 
B6/lpr-p21-/- T cells were detected by [3H] thymidine incorporation (B6/lpr, 4309 vs. B6/lpr-p21-/-, 
3903 cpm; p = 0.16) (Fig. 4.24B).
After 6 days of IL-2 expansion, T cells were restimulated with ConA to study the proliferative 
capacity of B6/lpr-p21-/- in comparison to B6/lpr effector/memory T cells in vitro.  As B6/lpr mice lack 
Fas, AICD is not found in B6/lpr T cells and low apoptosis levels were anticipated during secondary 
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stimulation.  Use of the apoptosis inhibitor zVAD was thus not necessary during restimulation 
of effector/memory T cells.  Comparison of cell cycle profiles at 24 h post-secondary stimulation 
showed higher proliferation rates for B6/lpr-p21-/- effector/memory than for B6/lpr T cells.  Apoptosis 
levels were similar in both cell types, although higher than predicted (Fig. 4.24C).  A [3H] thymidine 
incorporation assay demonstrated 2.5-fold higher proliferation rates for B6/lpr effector/memory 
T cells (B6/lpr, 4142 vs. B6/lpr-p21-/-, 10243 cpm; p = 0.006) at 48 h after a secondary TCR challenge 
(Fig. 4.24D).  CFSE dilution assay confirmed increased cell division of B6/lpr-p21-/- effector/memory 
T cells compared to B6/lpr effector/memory T cells in the course of secondary stimulation (Fig.4.24E). 
The results obtained with B6/lpr lymphocytes validate previous experiments with B6 T cells showing 
that lack of p21 increases hyperproliferation of memory-like T cells in vitro.
Figure 4.24.  Lack of p21 leads to hyperproliferation of B6/lpr CD4+ effector/memory T cells, but not naïve CD4+ T cells in 
vitro.  A. Cell cycle analysis of naïve B6/lpr and B6/lpr-p21-/-T cells at 24 h after primary ConA stimulation.  Representative 
histograms are shown (n = 4).  B. [3H] thymidine incorporation in B6/lpr and B6/lpr-p21-/- T cells at 24 h after primary TCR 
challenge (p = 0.16).  Values show mean ± SD (n = 4).  C. Cell cycle analysis of B6/lpr and B6/lpr-p21-/- effector/memory 
T cells at 24 h post-secondary stimulation.  Representative data are shown (n = 4).  D. [3H] thymidine uptake in B6/lpr and 
B6/lpr-p21-/- effector/memory T cells at 24 h after secondary ConA stimulation (p = 0.006).  Values show mean ± SD (n=4). 
E. CFSE dilution rate of PI- B6/lpr and B6/lpr-p21-/- effector/memory T cells at 72 h after secondary ConA stimulation. 
Representative histograms are shown (n = 2).
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Finally, we compared the proliferative capacity of B6, p21-/-, B6/lpr and B6/lpr-p21-/- effector/
memory T cells after a secondary TCR challenge.  A [3H] thymidine incorporation assay verified 
higher proliferation rates for p21-/- and B6/lpr-p21-/- T cells compared to the respective controls 
(B6 or B6/lpr), as observed in previous experiments (B6 vs. p21-/-, p = 0.039; B6/lpr vs. B6/lpr-p21-/-, 
p = 0.015).  Lack of Fas led to high proliferation levels for B6/lpr and B6/lpr-p21-/- T cells compared 
to B6 and p21-/- T cells (Fig. 4.25A).  This finding was confirmed by a CFSE dilution assay; B6/lpr-p21-/- 
T cells showed more cell divisions than p21-/- and B6/lpr T cells, while B6 control cells had the lowest 
proliferation rate (Fig.4.25B).  These data point to an additive effect of Fas and p21 in the control of 
effector/memory T cell proliferation in response to secondary TCR challenge in vitro.
Figure 4.25. FAS and p21 synergy in the control of memory-phenotype T cell proliferation.  A. Hyperproliferation of 
B6/lpr-p21-/- and p21-/- effector/memory T cells compared to their respective control T cells (B6/lpr and B6) at 48 h 
after secondary ConA stimulation was detected by [3H] thymidine uptake (B6 vs. p21-/-, p = 0.039; B6/lpr vs. B6/lpr-p21-/-, 
p = 0.015).  Values show mean ± SD (n = 2).  B. Dilution rate of CFSE-labeled PI- B6, p21-/-, B6/lpr and B6/lpr-p21-/- effector/
memory T cells at 96 h after restimulation with ConA.  Representative data are shown (n = 2).
4.3.5 Hyperactivated B6/lpr-p21-/- memory-phenotype T cells produce large amounts of pro-
inflammatory cytokines in vivo
NF-κB is crucial for appropriate T cell activation and pro-inflammatory cytokine production37. 
As we previously observed NF-κB hyperactivation of B6/lpr-p21-/- effector/memory T cells, we 
analyzed the activation state of memory T cell populations and the corresponding cytokine 
production in vivo. To evaluate cytokine production by different lymphocyte populations in 1-month-
old B6/lpr and  B6/lpr-p21-/- mice, we stimulated cells from secondary lymphoid organs (spleen 
or lymph nodes) ex vivo for 4 h with PMA and ionomycin, before intracellular staining for flow 
cytometry analysis (see 3.4.2).  In accordance with previous results, we observed higher production 
of IFNγ in total CD4+ T cells from B6/lpr-p21-/- mice compared to B6/lpr mice (Fig. 4.26A, left).  Both 
CD4+CD44highCD62Lhigh and CD4+CD44highCD62Llow memory T cell populations from B6/lpr-p21-/- mice 
showed high IFNγ production (Fig. 4.26A, middle and right).  In contrast, we detected no significant 
differences in production of IL-17 (Fig.4.26B) and IL-2 (data not shown).
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Figure 4.26.  Hyperactivated B6/lpr-p21-/- memory T cells produce large amounts of pro-inflammatory cytokines. 
A,B. Intracellular levels of IFNγ (A) and IL-17 (B) in splenocyte CD4+ and memory T cell populations from 1-month-old 
female B6/lpr and B6/lpr-p21-/- mice.  Ex vivo stimulation was performed with PMA (50 ng/ml) and ionomycin (2 μg/ml) at 
a concentration of 5 x 106 cells/ml.  A representative experiment is shown (n = 2).
As Fas-deficient mice are reported to develop autoimmune disease with age, we monitored 
aging B6/lpr and B6/lpr-p21-/- mice over time to analyze characteristic autoimmune parameters such 
as pro-flammatory cytokine production.  Ex vivo stimulation of splenocytes isolated from 8-month-
old females showed higher IL-17 levels in total CD4+ and memory cell populations from B6/lpr-
p21-/- mice (Fig. 4.27A).   In addition, we found a marked IL-2 increase in serum from  these mice 
(Fig. 4.27B).  Finally, we tested for IFNγ, a cytokine with an important role in autoimmune disease 
development140, and observed nearly three-fold higher IFNγ levels in CD4+ and memory T cells from 
B6/lpr-p21-/- compared to B6/lpr mice (Fig.4.27C).  Serum analysis confirmed high IFNγ levels in 
6-month-old B6/lpr-p21-/- mice (Fig.4.27D).
We found that pro-inflammatory cytokines are produced at elevated levels in B6/lpr-p21-/- 
compared to B6/lpr T cells; this might be a reason for the severe phenotype and increased mortality 
observed in B6/lpr-p21-/- mice.  We conclude that lack of p21 increases in vivo production of IFNγ, a 
cytokine closely linked to lupus development55.
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Figure 4.27.  Elevated levels of pro-inflammatory cytokines produced by CD4+ memory T cells from aging B6/lpr-
p21-/- mice.  A, C. Intracellular levels of IL-17 (A) and IFNγ (C) in splenocyte CD4+ and memory T cell populations from 
8-month-old female B6/lpr and B6/lpr-p21-/- mice.  Ex vivo stimulation was performed with PMA (50 ng/ml) and ionomycin 
(2 μg/ml) at a concentration of 5 x 106 cells/ml.  A representative experiment is shown (n = 2).  B,D. IL-2 (B) and IFNγ (D) 
levels in serum from 4 mice/strain (pool) were quantified by Luminex.
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4.4  p21 overexpression reduces T cell activation and autoimmunity development
Here we analyzed different p21-deficient mouse strains (B6, OT-II, pcc.TCRtg and B6/lpr) and 
found that CD4+ T cells, and especially effector/memory T cells, are hyperactivated in these mice. 
This hyperactivation state is translated into hyperproliferation of restimulated memory T cells in 
vitro and increased pro-inflammatory cytokine production.
To confirm the role of p21 in the T cell alterations described above, we reversed the p21-/- 
effects seen before by generating p21-overexpressing mice on the B6 and B6/lpr backgrounds 
(B6-p21tg and B6/lpr-p21tg).  These mice feature a human p21 transgene expressed constitutively 
under the T cell-specific Lck promotor106, which allows analysis of T cell-directed p21 overexpression 
and its impact on autoimmune manifestations.  p21-transgenic mice show normal development 
and T cell differentiation processes106, and thus represent an excellent model to study the role of 
hyperactivation and hyperproliferation of CD4+ T cells in autoimmune disease development.
4.4.1 T cell-specific p21 overexpression reduces IFNγ production in B6/lpr but not in B6 effector/
memory T cells
Increased levels of pro-inflammatory cytokines are associated with autoimmune disease 
development141.  In previous experiments, we found elevated lupus-linked IFNγ, IL17 and IL-2 in the 
absence of p21 (Fig. 4.26, 4.27).  As several studies suggest a crucial role for IFNγ in autoimmune 
disease development in lupus models61,140,141, we measured IFNγ production in B6 and B6-p21tg 
as well as B6/lpr and B6/lpr-p21tg CD4+ effector and memory T cells.  We found higher IFNγ levels 
in CD4+CD44highCD62Lhigh and CD4+CD44highCD62Llow T cells of Fas-deficient B6/lpr mice compared 
to B6 controls (Fig. 4.28A,B; left).  IFNγ production was greatly reduced in B6/lpr-p21tg T cells 
(Fig. 4.28A,B; bottom), whereas p21 overexpression did not alter IFNγ levels in B6-p21tg T cells (Fig. 
4.28A,B; top).  There were no significant differences in IL-17 and Il-2 cytokine expression in B6-p21tg 
and B6/lpr-p21tg mice (data not shown).
Autoimmune disease in B6/lpr mice is thought to originate from accumulation of 
CD4CD8-TCRβ+ (DN) and CD4+ memory T cells72,77.  In the presence of the p21 transgene in B6/lpr 
mice, both DN and memory T cell populations were substantially reduced (data not shown).  Together 
with lower IFNγ expression, this reduction led to decreased lymphadenopathy and ameliorated 
autoimmune manifestations in B6/lpr-p21tg mice.
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Figure 4.28.  T cell-specific p21 overexpression reduces IFNγ production in B6/lpr but not in B6 memory T cells. 
Intracellular levels of IFNγ in lymph node CD4+CD44highCD62Lhigh (A) and CD4+CD44highCD62Llow (B) memory T cell populations 
from 4-month-old B6, B6-p21tg, B6/lpr and B6/lpr-p21tg mice, as determined by flow cytometry.  Ex vivo stimulation 
was performed with PMA (50 ng/ml) and ionomycin (2 μg/ml) at a concentration of 5 x 106 cells/ml.  A representative 
experiment is shown (n = 2; 4 mice/strain).
4.4.2 Hyperactivation of CD4+ effector/memory T cells is reduced by p21 overexpression in 
B6/lpr-p21tg mice
As T cells were shown to be hyperactivated in the absence of p21 (Fig. 4.5), we analyzed 
the activation of various CD4+ effector/memory T cell populations in p21-overexpressing mice 
using CD69 as a cell surface activation marker143.  We observed a >4-fold higher activation level 
in CD4+CD44highCD62Lhigh T cells from B6/lpr mice compared to B6 controls (Fig. 4.29A, left).  p21 
transgene expression had no effect on B6 effector T cell activation (Fig. 4.29A, top panels), but 
clearly reduced CD4+CD44highCD62Lhigh T cell activation in B6/lpr mice (Fig. 4.29A, bottom panels).
Activation of CD4+CD44highCD62Llow memory T cells was only slightly increased in Fas-
deficient mice compared to B6 controls (Fig. 4.29B, left panels).  p21 overexpression had no effect 
on the high activation levels of memory B6 T cells (Fig. 4.29B, top panels), and activation levels of 
B6/lpr memory T cells also remained unaffected (Fig. 4.29B, bottom panels).
Exogenous p21 expression had no effect on the activation of B6 effector/memory T cells 
(Fig. 4.29A,B; top panels), but efficiently reduced activation of B6/lpr CD44highCD62Lhigh effector T cells 
(Fig. 4.29A, bottom panels), indicating a specific role for p21 in the regulation of hyperactivated 
Txcells.
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Figure 4.29.  Activation of CD4+ effector/memory T cells is reduced by p21 overexpression in B6/lpr-p21tg mice.  Surface 
expression of CD69 on lymph node CD4+CD44highCD62Lhigh (A) and CD4+CD44highCD62Llow (B) memory T cell populations from 
4-month-old B6, B6-p21tg, B6/lpr and B6/lpr-p21tg mice, as determined by flow cytometry.  A representative experiment 
is shown (n = 2; 4 mice/strain).
4.4.3 p21 overexpression reduces B6/lpr T cell proliferation after repeated in vitro stimulation
We previously showed the relevance of p21 in the control of T cell expansion after a 
secondary TCR stimulation.  To analyze the effect of p21 overexpression on T cell proliferation, 
we subjected freshly isolated B6 and B6-p21tg CD4+ T cells to our optimized repeated stimulation 
system in vitro (Fig. 4.4A).  We observed similar percentages of proliferation and apoptosis after 
ConA stimulation of naïve B6 and B6-p21tg CD4+ T cells (Fig. 4.30A), and [3H] thymidine uptake was 
comparable between both cell types (B6, 1352 vs. B6-p21tg, 1240 cpm; p = 0.652) (Fig. 4.30B).  In 
response to a secondary TCR challenge, however, B6 and B6-p21tg effector/memory T cells showed 
comparable proliferation levels, as indicated by cell cycle analysis (Fig. 4.30C).  Apoptosis levels 
remained unaffected by p21 overexpression (Fig. 4.31C).  A [3H] thymidine incorporation assay 
revealed slightly decreased proliferation rates in restimulated B6-p21tg effector/memory T cells (B6, 
8508 vs. B6p21tg, 16066 cpm, p = 0.03) (Fig. 4.30D).  We detected no major difference difference in 
the expansion of B6 and B6-p21tg effector/memory T cells, which indicates that overexpressed p21 
had little effect on T cell proliferation.
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Figure 4.30.  p21 overexpression does not affect effector/memory B6 T cell proliferation.  A. Cell cycle analysis of B6 and 
B6-p21tg T cells at 24 h after primary ConA stimulation.  Representative histograms are shown (n = 2).  B. [3H] thymidine 
uptake in B6 and B6-p21tg T cells at 24 h after primary TCR challenge with ConA.  Values show mean ± SD (n = 2; p = 0.652). 
C. Cell cycle profiles of B6 and B6-p21tg effector/memory T cells at 48 h after secondary stimulation in the presence of 
zVAD (12.5 μM).  Representative histograms are shown (n = 2).  D. [3H] thymidine uptake by B6-p21tg effector/memory T 
cells at 48 h after secondary TCR challenge in the presence of zVAD (12.5 μM).  Values show mean ± SD (n = 2; p = 0.03).
CD4+ T cells hyperproliferate in B6/lpr mice, a phenomenon implicated in development 
of autoimmune disease55,144; we thus examined the effect of T cell-specific p21 overexpression on 
B6/lpr T cell proliferation.  Cell cycle profiles of restimulated CD4+ T cells revealed a decreased 
percentage of proliferation of B6/lpr-p21tg compared to B6/lpr T cells (Fig. 4.31A). This observation 
was confirmed by a [3H] thymidine incorporation assay, which showed a significant reduction in 
T cell expansion in B6/lpr-p21tg compared to B6/lpr effector/memory T cells (B6/lpr, 26346 vs. 
B6/lpr-p21tg, 15448 cpm; p = 0.0003) (Fig. 4.31B).  Specific TCR stimulation with anti-CD3/CD28 
antibodies led to similar results (data not shown).
To analyze activation levels of B6/lpr and B6/lpr-p21tg CD4+ memory T cells following 
secondary TCR challenge in vitro, we used Western blot to monitor ERK1/2 phosphorylation over 
time.  We observed less phospho-ERK1/2 in B6/lpr-p21tg T cells up to 1 h post-stimulation compared 
to control counterparts, with maintained ERK1/2 hyperphosphorylation after 2 h (Fig. 4.32C).  We 
also detected a reduction in p21 transgene expression after secondary stimulation (Fig. 4.32C). 
High p21 expression levels at the beginning of secondary TCR challenge could explain the lower 
proliferative response during secondary stimulation.  We found that p21 overexpression regulated 
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hyperactivation and resulting hyperproliferation of B6/lpr-p21tg effector/memory T cells in vitro, 
whereas no significant effects were observed in B6-p21tg effector/memory T cells.
Figure 4.31.  B6/lpr T cell activation and proliferation is reduced by p21 overexpression.  A. Cell cycle analysis of B6/lpr 
and B6/lpr-p21tg effector/memory T cells at 24 h after secondary ConA stimulation.  Representative histograms are shown 
(n = 2).  B. [3H] thymidine uptake of B6/lpr and B6/lpr-p21tg effector/memory T cells at 48 h after secondary TCR challenge 
with ConA.  Values show mean ± SD (n = 2; p = 0.0003).  C. Western blot shows variations in ERK1/2 phosphorylation in 
B6/lpr-p21tg effector/memory T cells in response to secondary ConA stimulation (n = 3).
4.4.4 Exogenous p21 expression controls CDK2 and NF-κB activation in B6/lpr memory-
phenotype T cells
As we found that p21 overexpression reduced T cell hyperactivation and hyperproliferation 
in vitro and in vivo, and thus has an important regulatory role in B6/lpr-p21tg effector/memory T 
cells, we examined CDK2 activity in B6/lpr and B6/lpr-p21tg memory-phenotype T cells.  At 24 h 
after restimulation, CDK2 activity was clearly reduced in B6/lpr-p21tg effector/memory T cells (Fig. 
4.32A).  This fact could explain the decrease in effector/memory T cell proliferation in the presence 
of overexpressed p21, as p21 is able to induce cell cycle arrest in a CDK2-dependent manner.
In previous experiments, we identified NF-κB as an effector molecule responsible for 
hyperactivation of B6/lpr-p21-/- effector/memory T cells (Fig. 4.23B).  We thus tested NF-κB 
activation levels in B6/lpr and B6/lpr-p21tg effector/memory T cells in response to a secondary 
TCR challenge, to evaluate the effect of p21 overexpression on NF-κB activation.  EMSA showed 
lower NF-κB activity in B6/lpr-p21tg effector/memory T cells at 4 h and 24 h post-restimulation 
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(Fig. 4.32B).  The data indicated that exogenous p21 is able to control B6/lpr effector/memory T cell 
activation and proliferation via both CDK2 and NF-κB.
Figure 4.32.  p21 overexpression inhibits both CDK2 and NF-κB activity in B6/lpr effector/memory T cells.  A. CDK2 
activity levels in B6/lpr and B6/lpr-p21tg effector/memory T cells at indicated times after secondary ConA stimulation, 
as determined by a CDK2-specific kinase assay.  A representative experiment is shown (n = 2).  B. NF-κB activation levels 
in B6/lpr and B6/lpr-p21tg effector/memory T cells after secondary stimulation as detected by EMSA.  A representative 
experiment is shown (n = 2).
4.4.5 p21 overexpression reduces pro-inflammatory cytokine production of B6/lpr memory-
phenotype T cells in vitro
In accordance with our finding that p21 overexpression reduced hyperactivation of 
B6/lpr effector/memory T cells in vitro, we detected notably decreased IFNγ production in response 
to secondary stimulation (Fig. 4.33A). To confirm that the reduction observed was due to p21 
overexpression in B6/lpr T cells, we induced IFNγ production directly by secondary stimulation with 
IL-12 and IL-18.  Together, IL-12 and IL-18 trigger IFNγ production in a TCR-independent manner145,146, 
and in our system strongly induced IFNγ expression in B6/lpr effector/memory T cells (Fig. 4.33B, 
left).  In B6/lpr-p21tg effector/memory T cells, IFNγ production was markedly reduced (Fig. 4.33B, 
right), which confirmed our hypothesis that p21 overexpression negatively controls IFNγ induction 
in effector/memory T cells.
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Figure 4.33.  Enhanced p21 expression dampens IFNγ induction by IL-12 and IL-18.  A. Percentages of IFNγ-producing 
B6/lpr and B6/lpr-p21tg effector/memory T cells at 24 h after secondary stimulation with (A) PMA and ionomycin or 
(B) IL-12 and IL-18 (10 μg/ml).  Values show mean ± SD (A: n = 4 T cell preparations from distinct mice; p <10-2; B: n = 3, 
px= 0.0013).
p21 overexpression considerably reduced B6/lpr effector/memory T cell activation and pro-
inflammatory cytokine production, pointing to an autoimmune-suppressing function of p21.  Indeed, 
exogenous p21 expression ameliorated lupus development and notably reduced death rates (data 
not shown).  p21 could possibly have a role in therapeutic approaches for autoimmune diseases.
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5.1 p21 is involved in effector/memory T cell activation
A delicate balance between T cell activation, proliferation and death is responsible for 
establishing and maintaining T cell tolerance, a crucial characteristic of the immune system.  In a 
work previously published, we found that lack of p21 leads to hyperactivation, and in consequence to 
hyperproliferation of effector/memory T cells and development of mild lupus-like disease56.  The way 
how p21 influences T cell activation nonetheless remained elusive, as massive hyperproliferation of 
effector/memory T cells was not detectable in p21-/- mice in vivo.  Here we used diverse experimental 
approaches to confirm a possible role of p21 in effector/memory T cell activation and to gain further 
insight into the regulatory function of p21 in this process.
5.1.1 Subcellular localization of p21 is crucial for differential regulation of T cell activation
The most prominent role of p21 is its well-known function as a cell cycle inhibitor in response 
to extracellular signals.  Following DNA damage, p21 is translocated into the nucleus, where it 
suppresses CDK2 activity and thus blocks cell cycle progression97.  After successful DNA repair, p21 
is degraded and the cell cycle proceeds to S phase147,148.  Depending on its subcellular localization, 
however, endogenous p21 exerts distinct functions within eucaryotic cells.
In the present study, we observed very low levels of nuclear p21 in effector/memory T cells 
in response to activation (Fig. 4.9A).  This finding supports our hypothesis that p21 has a function 
in effector/memory T cells other than cell cycle regulation, as direct p21-CDK2 interaction would 
require nuclear presence of p21.
We also observed increasing p21 levels in cytoplasm after TCR stimulation (Fig. 4.9).  The 
cytoplasmic location enables p21 interaction with various molecules involved in T cell activation 
pathways.  TCR-specific and intracellular stimulation with the DAG analog PMA resulted in similar 
Txcell responses (Fig. 4.8), excluding the possibility that p21 regulates early steps in T cell activation. 
PMA directly stimulates PKCθ, bypassing TCR proximal events; p21 might therefore act on PKCθ or 
in downstream pathways that lead to T cell activation.
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5.1.2 Regulation of effector/memory T cell activation by p21 is not dependent on CDK2
Following TCR stimulation, a highly conserved regulatory apparatus coordinates cell cycle 
progression and links extracellular signals to cellular responses, inducing a complex series of events 
that leads to cell division.  The G1-S phase transition is initiated by the assembly of cyclinD-CDK4/6 
complexes and subsequent activation of cyclinE/A-CDK2, considered a key step for induction of DNA 
synthesis149,150.  Cyclin/CDK complexes phosphorylate pRb molecules and trigger E2F2-mediated 
transcription of genes that promote cell cycle progression (Fig. 1.6).  In its role as a cell cycle 
inhibitor, p21 regulates cyclinE/CDK2 complex activity and is able to induce cell cycle arrest at this 
point85,88.  In agreement, we observed dysregulated CDK2 activity in naïve T cells that lacked p21; 
CDK2 was hyperactivated at 72 h due to the absence of p21 in CD4+ T cells (Fig. 4.1B).  In WT T cells, 
p21 expression was evident at 48 h after primary stimulation (Fig. 4.1A) and its presence efficiently 
controlled CDK2 activity (Fig. 4.1B).  This observation suggests that p21 is a negative regulator of 
CDK2 activity following activation of naïve T cells.  We nonetheless observed no growth alteration in 
p21-deficient naïve T cells up to 48 h post-TCR stimulation (Fig. 4.3).  Longer exposure to stimulants 
leads to some hyperproliferation of p21-/- T cells56, which could be associated to altered CDK2 
activity or be driven by re-encounter with the same antigen.  In this study, we provide evidence that 
activation of naïve and effector/memory T cells are differentially regulated, although controlling 
elements other than CDK2 remain to be identified.
Although p21 regulates proliferation in fibroblasts in a CDK2-independent manner151, in 
CD4+ effector/memory T cells, the scenario for cell cycle regulation appeared to be different.  p21 
expression was observed shortly after secondary TCR challenge (Fig. 4.4B), but CDK2 activity was 
not influenced by lack of p21 (Fig. 4.7A,B).  This finding coincides with the observation of low p21 
levels in the nucleus of effector/memory T cells, suggesting minor importance of the p21-CDK2 
interaction for T cell activation in these cells.  Significant hyperproliferation of p21-/- effector/memory 
T cells was nevertheless observed after TCR stimulation (Fig. 4.6), which implied CDK2-independent 
control of memory T cell expansion by p21.  This observation is supported by other studies showing 
that CDK2 is not essential for cell cycle inhibition152,153.  To confirm this finding, we treated naïve and 
effector/memory T cells with the CDK2-specific inhibitor CVT-313124,125.  Proliferation of naïve T cells 
was greatly reduced (Fig. 4.7E), whereas the inhibitory effect of CVT-313 was less pronounced in 
effector/memory T cells (Fig. 4.7D).
p21-mediated inhibition of CDK2 activity is thus not an essential mechanism in activation 
control of specific cell types such as CD4+ effector/memory T cells, and other regulatory mechanisms 
are likely to influence T cell activation and proliferation.
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5.1.3 p21 negatively regulates activation of memory-like T cells after repeated stimulation
Interaction of the TCR with its antigen initiates a variety of signaling cascades, resulting in 
T cell activation and subsequent realization of its effector functions.  After primary stimulation of 
naïve CD4+ T cells, we observed comparable expression of CD69/CD25 activation markers (Fig. 4.2A), 
and intracellular activation indicators such as ERK1/2 phosphorylation did not show substantial 
differences in the absence of p21 (Fig. 4.2B).  In accordance with this finding, we detected similar 
proliferation levels of naïve B6 and p21-/- CD4+ T cells in response to ConA stimulation (Fig. 4.3).  These 
results indicate that late p21 expression does not influence activation and subsequent proliferation 
of naïve CD4+ T cells after primary TCR challenge.
More detailed analysis of CD4+ T cells in p21-/- mice showed an elevated proportion of 
CD4+CD69+ memory T cells (Fig. 4.5A).  The ERK1/2 phosphorylation pattern also appeared to 
be altered in the absence of p21, with a prolonged hyperphosphorylated state in p21-/- effector/
memory T cells (Fig. 4.5B).  ERK1/2 downstream effector molecules such as the transcription factor 
AP-1 reflected the hyperactivation of p21-deficient effector/memory T cells (Fig. 4.5C), which led 
to increased production of the pro-inflammatory cytokines IL-17, IL-2 (Fig. 4.5D) and IFNγ in vitro 
(Fig. 4.5E, top).  High IFNγ levels were also detected in effector/memory T cells of 1-year-old p21-/- 
mice in vivo (Fig. 4.5E, bottom), which supports the physiological significance of this finding.  The 
hyperactive state of p21-deficient effector/memory T cells was translated to extended proliferation 
of p21-/- effector/memory cells (Fig. 4.6, 4.15B-D and 4.18D,E), and an increased proportion of 
CD4+CD44highCD62Llow p21/ T cells in vitro (Fig. 4.15F) compared to B6 effector/memory T cells in 
response to secondary antigen encounter.
To show that these results are not a peculiarity of the ConA system, we used a specific 
antigen for repeated in vitro stimulation.  In this biologically relevant approach, we exposed T cells 
that presented a transgenic TCR to OVA-loaded dendritic cells (DC) (see 3.2.6).  We found similar 
activation of OT-II and p21-/- OT-II cells after primary stimulation (Fig. 4.14); however, p21-/- OT-II 
effector/memory T cells were hyperactivated and proliferated at higher rates than their control 
counterparts in response to secondary TCR stimulation (Fig. 4.15, 4.16).  In vivo challenge of 
adoptively transferred CD4+ T cells with OVA-presenting DC and subsequent restimulation ex vivo 
led to similar results (Fig. 4.17; see 3.3).  These data confirmed our hypothesis that p21 acts as a 
regulator of effector/memory T cell activation.
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5.2 p21 controls ERK1/2 and NF-κB signaling pathways in effector/memory T cells
The absence of p21 leads to hyperactivation and thus to hyperproliferation of effector/
memory T cells in response to a second antigen encounter.  To better understand the regulatory 
role of p21 in intracellular processes initiated by TCR stimulation, we analyzed two major signaling 
pathways crucial for T cell activation, ERK1/2 and NF-κB.
5.2.1 p21 limits late ERK activation in effector/memory T cells
Following TCR stimulation, early activation events lead to calcium influx and initiation of 
distinct pathways such as the MAPK cascade.  In accordance with our observations indicating that 
p21 is not involved in TCR proximate events (Fig. 4.8), we detected no differences in Ca2+ mobilization 
after TCR engagement in the absence of p21 (Fig. 4.10).  Within the MAPK cascade, however, both 
ERK1/2 and its downstream effector AP-1 appeared to be hyperactivated in p21-deficient effector/
memory T cells compared to controls (Fig. 4.5B,C), leading to elevated pro-inflammatory cytokine 
production (Fig. 4.5D).  To show that ERK1/2 hyperphosphorylation in the absence of p21 is also 
responsible for the hyperproliferation observed in p21-/- effector/memory T cells, we used an 
inhibitor that selectively interrupts MAPK cascade signal transduction and thus inhibits ERK1/2 
phosphorylation122.  Inhibition of ERK1/2 phosphorylation led to a significant reduction in p21-/- 
effector/memory T cell hyperproliferation (Fig. 4.11B-D), which confirmed an important role for p21 
in the control of MAPK activation.  The precise way in which p21 regulates ERK1/2 phosphorylation 
requires further study, although preliminary data from our lab indicate the involvement of Traf6 and 
the PI3K subunit p85 in this process.
Other systems show similar Ca2+ influx levels, although with elevated ERK1/2 
phosphorylation; this is the case for DGKζ-/- or DGKα-/- mice154,155.  These mice develop normally, but 
show hyperresponsiveness to TCR stimulation.  DGK (diacylglycerol kinase) terminate DAG signaling 
by catalyzing its phosphorylation and, in consequence, influence PKCθ activity; it would thus be of 
interest in future studies to investigate the possible relation of p21 with this pathway.
Treatment of B6 and p21-/- memory T cells with the ERK1/2 inhibitor excluded the possibility 
that T cell activation is CDK2-dependent (Fig. 4.11E), which supports the hypothesis that p21 controls 
T cell activation via ERK1/2 rather than via CDK2.  We observed that auto-reactive effector/memory 
T cells (p21-/-) were more susceptible than controls to inhibition of ERK1/2 phosphorylation by the 
inhibitor concentrations used here (Fig. 4.11B-D), indicating an important p21 function in MAPK 
activation following secondary T cell stimulation.
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As ERK1/2 activation after TCR-dependent stimulation advances in two main phases136, we 
analyzed whether early ERK1/2 phosphorylation is sufficient to induce hyperproliferation in p21-
deficient memory T cells or if later hyperactivation is required.  Proliferation was reduced significantly 
only in p21-deficient T cells (not in B6 controls), and inhibitor addition after 6 h was sufficient to limit 
hyperproliferation of p21-/- effector/memory T cells (Fig. 4.12B,C).  p21 thus controls the proliferative 
response of effector/memory T cells via late ERK1/2 activation, and ERK1/2 hyperphosphorylation 
in the absence of p21 promotes extensive T cell proliferation after TCR restimulation.
5.2.2 p21 controls T cell activation via the NF-κB activation pathway
One of the pathways commonly used to detect T cell activation is the nuclear translocation 
of the transcription factor NF-κB in response to TCR stimulation.  NF-κB triggers expression of pro-
inflammatory cytokines such as IL-2 and IFNγ, as well as transcription of crucial genes involved in 
T cell proliferation and survival.  A previous study from our laboratory showed that p21 regulates 
NF-κB activation in macrophages111.
In the absence of p21, we observed substantial hyperactivation of NF-κB in response to 
secondary TCR challenge with ConA or OVA (Fig. 4.13A-C, 4.16B).  As early as 1 h after restimulation 
of effector/memory T cells, we detected elevated NF-κB activity levels that reached maximum at 
48 h post-stimulation.  To determine whether NF-κB hyperactivation affected the p21-/- effector/
memory T cell hyperproliferation, we treated memory-like T cells with BAY11-7082, a specific inhibitor 
of NF-κB activation.  Prevention of NF-κB activation led to a significant reduction in proliferation by 
restimulated p21-deficient T cells (Fig. 4.13D), confirming that elevated NF-κB activity is associated 
with hyperproliferation of effector/memory T cells in the absence of p21.  This inhibitory effect 
was even stronger when we inhibited NF-κB at a later time after initiation of secondary T cell 
stimulation (Fig. 4.13E); thus, in addition to ERK phosphorylation, the hyperactive state and the 
subsequent hyperproliferation of p21-deficient effector/memory T cells depends critically on late 
NF-κB hyperactivation.
Both ERK1/2 and NF-κB have crucial physiological functions in the immune system37; it is 
thus not surprising that several studies related hyperactivation of ERK1/2 or NF-κB with pathological 
manifestations in human autoimmune diseases such as ALPS, SLE or RA81,156.  These autoimmune 
diseases are also linked to excessive lymphoproliferation.
The observation that inhibitors of ERK1/2 and NF-κB activity specifically reduced 
p21-deficient effector/memory T cell hyperproliferation suggests that, in specific conditions, 
potentially auto-reactive T cells are more susceptible to inhibitor treatment.  Several murine 
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models of human autoimmune diseases confirmed the therapeutic potential of these inhibitors. 
Decreased hyperactivation of the MAPK cascade by treatment with Ras inhibitor leads to reduced 
lymphadenopathy and lower anti-DNA antibody levels in MRL/lpr mice157, and specific inhibition 
of NF-κB has an important anti-inflammatory effect in several arthritis models158,159.  In addition to 
NF-κB, we found higher AP-1 activity p21-/- effector/memory T cells (Fig. 4.5C).  This observation was 
anticipated, as AP-1 is a direct effector of phosphorylated ERK1/2, which showed high activity levels 
in the absence of p21 (Fig. 4.5B).
Although both AP-1 and NF-κB were overactivated in the absence of p21, this observation 
does not represent a general characteristic of effector/memory T cells.  NFAT, another transcription 
factor essential for T cell activation, was not hyperactivated immediately after TCR stimulation 
(Fig. 4.10B), and its later hyperactivation might be due to feedback mechanisms induced by other 
pathways hyperactivated due to lack of p21.
The constitutive hyperactivation of both ERK1/2 and NF-κB pathways in p21-/- effector/
memory T cells led not only to increased proliferation, but also to elevated production of pro-
inflammatory cytokines such as IFNγ and IL-2 (Fig. 4.5D,E).  High IFNγ expression was closely linked to 
development of lupus-like disease140.  Our data suggest a protective function of p21 in autoimmune 
disease development, as it controls effector/memory T cell activation via the ERK1/2 and NF-κB 
pathways.
5.2.3 Model for the differential regulation of tolerance establishment and maintenance by p21 
in naïve and memory-phenotype T cells
In this study, we define distinct roles for p21 in the immune response of T cells after repeated 
TCR stimulation.  As observed here, p21 is expressed relatively late (more than 48 h) after TCR 
stimulation, and subsequently controls cell cycle progression by interacting with CDK2, a known and 
extensively studied p21 function (Fig. 5.1A).
In effector/memory T cells, we identified a previously unreported function for p21 as an 
activation regulator.  After TCR challenge, p21 is expressed within a few hours and controls effector/
memory T cell activation by inhibiting main activation pathways.  In contrast to its classical function, 
p21 limits effector/memory T cell activation in a CDK2-independent manner (Fig. 5.1B).  In its role 
as a negative regulator of ERK1/2 and NF-κB activity, cytoplasmic p21 efficiently limits effector/
memory T cell proliferation.
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Figure 5.1.  Differential regulation of T cell activation by p21.  A. The classical role of p21, as currently accepted. 
B. A novel role for p21: In response to repeated stimulation, p21 negatively regulates effector/memory T cell activation 
and subsequent proliferation.
5.3 p21 influences the activation threshold of effector/memory T cells
During T cell development, potentially auto-reactive lymphocytes are inactivated or directly 
eliminated.  Some auto-reactive T cells are able to escape negative selection in the thymus and 
originate autoimmune diseases; in peripheral tissues, autoimmune T cells might be activated by 
auto-antigens, which have low affinity for the TCR139.
To examine whether p21 has a role in determining the activation threshold in effector/memory 
T cells, we analyzed the T cell response by presenting a transgenic TCR stimulated with antigens 
of high (PCC, representing exogenous antigens) or low affinity (A96I, representing endogenous 
antigens) for this TCRtg.  During primary ConA stimulation, we detected no significant differences in 
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proliferation between naïve pcc.TCRtg and pcc.TCRtg-p21-/- T cells in response to primary stimulation 
with PCC (Fig. 4.18B,C).  Following secondary TCR challenge with the same antigen, however, p21-
deficient pcc.TCRtg memory-phenotype T cells showed considerable hyperproliferation and high 
levels of apoptosis were induced (Fig. 4.18D,E), indicating a strong stimulating effect of PCC.  When 
stimulated with PCC and restimulated with a low affinity antigen (A96I), pcc.TCRtg-p21-/- effector/
memory T cells clearly hyperproliferated in response to A96I (Fig. 4.19A); the proliferation difference 
between pcc.TCRtg and pcc.TCRtg-p21-/- memory T cells was even greater than after restimulation 
with PCC.  These findings define a model in which p21 modulates the activation threshold of 
effector/memory T cells, as its absence leads to a reduction in this threshold and enables T cell 
responses to low affinity peptides.  As a result, these overactivated effector/memory T cells lose 
tolerance, leading to development of autoimmunity. p21 expression prevents immune responses to 
auto-antigens with low TCR affinity and could thus have an important function in the establishment 
of T cell tolerance and in autoimmune suppression.
5.4 Lack of p21 exacerbates the autoimmune phenotype in B6/lpr mice
Fas-deficient mice develop lupus-like autoimmune disease due to defective apoptosis 
signaling.  One of the most common manifestations is glomerulonephritis, caused by chronic 
inflammation and immune complex accumulation (see 1.1.2).  In B6/lpr mice, a mild course of 
disease is generally observed.  To establish the biological significance of the p21 function in Txcell 
activation in vivo, we generated B6/lpr-p21-/- mice in our laboratory and found higher disease 
incidence in these mice.
In vitro analysis of B6/lpr-p21-/- memory-like T cells revealed a hyperactive state after 
secondary stimulation; both ERK1/2 and NF-κB were hyperactivated (Fig. 4.23A,B).  Production of 
pro-inflammatory cytokines by B6/lpr-p21-/- effector/memory T cells was thus notably increased 
compared to B6/lpr controls (Fig. 4.23D).  We also observed significant B6/lpr-p21-/- effector/memory 
T cell hyperproliferation in response to repeated TCR challenge (Fig. 4.24); Fas and p21 showed an 
additive effect in the control of effector/memory T cell proliferation in response to secondary TCR 
challenge (Fig. 4.25).  The in vitro findings were similar to the characteristics observed in B6 and 
p21-/- mice, but more severe.  This suggests p21 involvement in processes that lead to autoimmune 
disease development.
To study the effect of p21 deficiency on autoimmune manifestations in vivo, we analyzed 
several T cell populations in B6/lpr and B6/lpr-p21-/- mice and their implication in disease 
development.  Lack of p21 led to clear hyperactivation of CD4+ effector/memory T cells in 1-year-
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old B6/lpr-p21-/- mice (Fig. 4.22B) and thus to CD44highCD62Llow T cell accumulation in secondary 
lymphoid organs (Fig. 4.22A), an autoimmune characteristic typical of several models of lupus-
like disease56,60,160.  In addition, we found higher expression of the pro-inflammatory cytokines 
IFNγ, IL-17 and IL-2 in CD4+CD44highCD62Lhigh and CD4+CD44highCD62Llow memory T cells from 
p21-deficient B6/lpr mice (Fig. 4.27, 4.28).  In accordance with these findings, B6/lpr-p21-/- mice 
developed severe glomerulonephritis (Fig. 4.20A) and pronounced proteinuria (Fig. 4.20B).  The 
lack of p21 did not alter DN T cell proliferation or accumulation in B6/lpr mice (Fig. 4.21B), and 
lymphadenopathy manifestations remained unchanged (data not shown).  This observation raises 
the possibility that hyperactivated B6/lpr-p21-/- effector/memory T cells are involved in development 
of autoimmunity. p21 deletion had a strong effect on B6/lpr mice and caused serious aggravation of 
pathological manifestations, including increased B6/lpr effector/memory T cell activation, elevated 
IFNγ production, severe glomerulonephritis and lethal disease development.  This animal model 
confirmed the biological relevance of our findings, suggesting an autoimmune suppressor function 
for p21.
5.5 Overexpression of p21 reduces hyperactivation of B6/lpr effector/memory T cells and 
ameliorates autoimmune manifestations
To provide the final demonstration of p21 involvement in the regulation of memory 
Txcell activation and to show its therapeutic potential, we used a mouse model characterized by 
expression of transgenic human p21 in a T cell-specific manner106.  In a recently published article by 
our group, we report that T cell-directed exogenous expression of p21 leads to reduced production 
of pro-inflammatory cytokines, less immune complex deposition in kidneys and decreased anti-
DNA autoantibody production in MRL/lpr-p21tg mice161.  As a result, the usually severe outcome 
of the autoimmune disease in MRL/lpr mice was clearly improved and early mortality (due to the 
autoimmunity-prone MRL background) was restricted in the MRL/lpr-p21tg mice161.
An important characteristic of lupus-like diseases is the development of anti-DNA 
autoantibodies, which is closely linked to high IFNγ levels55,162.  We showed that reduced IFNγ 
production by B6/lpr-p21tg T cells leads to a notable reduction in auto-antibody levels161, 
indicating that p21 overexpression is able to ameliorate the outcome of autoimmune disease. p21 
overexpression did not alter activation of B6-p21tg effector/memory T cells or their IFNγ expression 
(Fig.4.28, 4.29), which indicates that endogenous p21 expression is sufficient to control the immune 
response of B6 effector/memory T cells.  In contrast, higher p21 levels are necessary to control 
activation of B6/lpr-p21tg effector/memory T cells after stimulation, which suggests a specific role 
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for p21 in negative regulation of activation events and immune responses of auto-reactive T cells.
In B6/lpr effector/memory T cells, expression of exogenous p21 efficiently reduced in vitro 
hyperactivation, as reflected by ERK1/2 phosphorylation (Fig. 4.31C) and NF-κB activity levels (Fig. 
4.32B).  In addition, hyperproliferation of B6/lpr effector/memory T cells notably decreased in 
response to secondary TCR challenge, due to transgenic p21 expression (Fig. 4.31A,B).  This can be 
attributed, at least in part, to the reduced CDK2 activity in B6/lpr-p21tg effector/memory T cells (Fig. 
4.32A).  We detected no differences in B6-p21tg effector/memory T cell activation and expansion 
(Fig. 4.30), however; p21 thus does not act as a negative regulator of B6 T cell proliferation via CDK2. 
In accordance with their less activated phenotype, B6/lpr-p21tg effector/memory T cells produced 
lower amounts of IFNγ than B6/lpr memory T cells (Fig. 4.33A).  p21 overexpression notably inhibited 
IFNγ induction after IL-12 and IL-18 stimulation (Fig. 4.33B).
p21 expression is also an important factor in human autoimmune disease.  A study of SLE 
patients showed low p21 and p27 expression in hyperproliferating T cells of some patients; however, 
treatment with FasL induced p21 expression, which ameliorated disease manifestations163.  p21 is 
thus an essential factor in the control of hyperactivation in autoimmune-prone but not in normal 
effector/memory T cells, and could be a suitable target for the design of new treatment strategies 
to reduce lymphoproliferation in autoimmune diseases.
5.6  Concluding remarks
Imbalanced tolerance of the immune system generates auto-reactive T cells and thus 
presents a threat to health.  A variety of mechanisms during T cell development prevent the 
appearance of T cells able to respond to self-antigens, and several intrinsic mechanisms ensure 
adequate T cell function.
Here we describe an unreported function for p21, and show its implication in the regulation 
of memory-phenotype T cell activation; its absence leads to hyperactivation and therefore to 
hyperproliferation of p21-/- memory T cells.  We showed that p21 targets intracellular activation 
pathways such as ERK1/2 and NF-κB, whereas its interaction with CDK2 appeared to be of minor 
importance.  In addition, overactivated p21-/- effector/memory T cells responded to autoantigen-
mimicking molecules with low affinity for the TCR, indicating a p21 function in modulation of the 
TCR activation threshold.
The biological relevance of these findings was demonstrated in several mouse models 
(summarized in Fig. 5.2).  In B6/lpr mice, which typically present mild autoimmune manifestations, 
106
5. DISCUSSION
lack of p21 led to development of severe autoimmunity and high death rates.  B6/lpr-p21-/- T cells 
were hyperactivated and produced large amounts of IFNγ; these factors are known to promote loss 
of tolerance and autoimmunity development.  Both Fas and p21 thus appear to have autoimmune 
suppressive functions, although they do not play an essential role in normal immune responses.
T cell-specific overexpression provided direct evidence for p21 as negative regulator of 
autoimmunity.  B6/lpr-p21tg effector/memory T cells showed notably decreased activation as well 
as reduced IFNγ expression.  As a consequence, autoimmunity in B6/lpr mice was ameliorated 
considerably due to enhanced p21 expression in T cells.  p21 overexpression nonetheless had little 
or no effect on T cell activation in B6 mice, pointing to a specific role for p21 in autoimmune, but 
not normal immune responses.
In general, p21 might not be a strong inhibitor of T cell activation, but it appears to control 
specifically the activity of autoreactive effector/memory T cells.  Low p21 expression164,165 and 
elevated levels of pro-inflammatory cytokines such as IFNγ166,167 are important characteristics of 
several autoimmune diseases, including human SLE.  Based on our findings, IFNγ production by 
hyperactivated T cells is negatively controlled by p21, which is thus an optimal target for therapeutic 
strategies directed to autoimmune cells.
As design of therapies based on molecules with an essential role in T cell activation has 
failed to be of benefit in autoimmune disease treatment, perhaps less potent molecules that appear 
to be specific for autoimmune T cell function will constitute a more efficient therapeutic target for 
autoimmune disease15-18,54.
Figure 5.2.  Overview of phenotypes observed in the mouse models used in this study.  Glomerulonephritis grades were 
determined according to the scale defined by Weening et al.132 (NA = not assessed).
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p21 controls activation of memory-phenotype T cells after repeated TCR stimulation in 1. 
a CDK2-independent manner, but has no effect on naïve T cells.  Stimulation of TCRtg 
T cells with a specific antigen (OVA) confirmed the hypothesis that p21 is involved in 
activation of effector/memory T cells in an in vivo setting.     
p21 is unrelated to TCR proximate events, but might act on PKCθ or on downstream 2. 
activation pathways, as it is located in the cytoplasm of CD4+ effector/memory T cells. 
 
p21 negatively regulates the proliferative response of effector/memory T cells via ERK1/2 3. 
and NF-κB activation pathways.  In the absence of p21, memory-phenotype T cells show 
hyperactivation of both ERK1/2 and NF-κB, which leads to increased proliferation and 
pro-inflammatory cytokine production (IFNγ, IL-2).      
p21-deficient pcc.TCRtg effector/memory T cells are more susceptible to activation 4. 
by antigens with low TCR affinity that mimic auto-antigens, which suggests that p21 
regulates the activation threshold and thus maintains tolerance and suppresses 
autoimmunity.          
B6/5. lpr-p21-/- mice confirmed the in vivo biological relevance of our findings.  Absence 
of p21 caused increased activation of memory T cells and elevated production of pro-
inflammatory cytokine such as IFNγ, leading to notable aggravation of lupus-like disease 
manifestations and death in B6/lpr mice.       
Constitutive p21 overexpression by T cells efficiently reduced pathological manifestations 6. 
in B6/lpr-p21tg mice.  Lower IFNγ levels represent a critical feature of the reduced 
activation, since they control loss of tolerance and lupus development.   
p21 is an autoimmunity suppressor that acts by inhibiting T cell activation and reducing 7. 
pro-inflammatory cytokine production by auto-reactive, but not by normal T cells after 
repeated antigen encounter, and thus might have therapeutic relevance.
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p21 controla la activación de células T de memoria/efectoras de manera independiente a 1. 
CDK2 después de una estimulación repetida del TCR, sin influir la activación de las célulasxT 
naïve. La estimulación de células con un TCR transgénico con el antígeno específico OVA in 
vivo confirma el papel p21 en la activación de células T de memoria/efectoras.   
p21 está localizado en el citoplasma de las células T de memoria/efectoras y no está 2. 
involucrado en la cascada de activación próxima al TCR, ya que actúa a nivel de la PKCθ o 
en las vías de activación reguladas por esta quinasa.      
p21 controla de manera negativa la respuesta proliferativa de las células T de memoria/3. 
efectoras regulando las vías de activación de ERK1/2 y NF-κB. La ausencia de p21 en las 
células de memoria causa la sobreactivación de ERK1/2 y NF-κB de estas células y, en 
consecuencia, su hiperproliferación y una mayor producción de citoquinas pro-inflamatorias 
(IFNγ, IL-2).           
Las células T de memoria/efectoras deficientes en p21 con un TCR transgénico (pcc.TCRtg-4. 
p21-/-) tienen una alta susceptibilidad a activarse frente a antígenos de baja afinidad, 
sugiriendo que p21 juega un papel en el control del umbral de activación de las célulasxT 
de memoria/efectoras. De ésta manera, p21 ayuda a mantener la tolerancia frente a 
antígenos propios y a suprimir el desarrollo de autoinmunidad.     
Los ratones B6/5. lpr deficientes en p21 (B6/lpr-p21-/-) confirman la relevancia biológica 
de nuestros resultados: en ausencia de p21, las células T de memoria/efectoras están 
hiperactivadas y producen elevadas cantidades de citoquinas pro-inflamatorias como IFNγ. 
Como consecuencia, se produce un aumento en las manifestaciones de la enfermedad 
autoinmune en los ratones B6/lpr que finalmente causa su muerte.    
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En ratones B6/6. lpr-p21tg, la sobre-expresión constitutiva de p21 de manera específica en 
las células T reduce las manifestaciones patológicas de los ratones deficientes en FAS de 
forma eficaz. La disminución en los niveles de IFNγ es un elemento crítico en la reducción 
de la activación de las células T, ya que esta citoquina controla la pérdida de tolerancia y el 
desarrollo de la enfermedad autoinmune.       
 
p21 es un potente supresor de autoinmunidad y ejerce su función inhibiendo la activación 7. 
y la producción de citoquinas pro-inflamatorias de las células T potencialmente auto-
reactivas en respuesta a una estimulación repetida, sin afectar a células T normales. Por 
lo tanto, p21 podría ser relevante para el diseño de nuevas terapias en el tratamiento de 
enfermedades autoinmunes.
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